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ABSTRACT
Ricin B Chain-Insulin Fusion Protein Immunomodulation of Type 1 Diabetes
by
James Edward Carter III
Doctor of Philosophy, Graduate program in Biochemistry
Loma Linda University, June 2010
Dr. William H. R. Langridge, Chairperson
Type 1 diabetes mellitus (T1D) is a debilitating chronic inflammatory disease of
the insulin-producing pancreatic islet P-cells that results from a combination of genetic
and environmental factors. Attempts to suppress Thl-mediated autoimmune diseases
such as T1D by mucosal delivery of autoantigens for immunotolerization have yielded
only partial success. Attainment of satisfactory levels of sustained immunological
tolerance remains to be accomplished. To restore self-tolerance requires delivery of
sufficient amounts of autoantigen to stimulate regulatory T helper cells that function to
survey the gut and induce tolerance to consumed antigens such as food. Oral delivery of
autoantigens has previously been shown to elicit IL-4, IL-10, and TGF-|3 suppressor
cytokine release by regulatory T-cells, but large autoantigen doses are usually required to
overcome protease degradation in the gut.
To enhance the effectiveness of oral tolerance therapy, the diabetes autoantigen
proinsulin was linked to the non-toxic B chain of ricin—an enterocyte-binding plant
lectin that possesses intrinsic cell-delivery and immunostimulatory properties. The
human proinsulin (INS) ricin toxin B chain (RTB) fusion protein was expressed in
Escherichia coli and purified for use in an animal inoculation experiment to test for the
suppression of diabetes symptoms. Non-obese diabetic (NOD) mice were orally

xvm

inoculated and boosted with purified INS-RTB. Histopathological examination of
immunized mouse pancreatic tissue showed significantly less lymphocyte infiltration into
pancreatic islets of Langerhans (regions of insulin production by p-cells) than did mice
dosed with INS alone or in untreated animals.
The bacterial-produced INS-RTB was synthesized as a denatured aggregate that,
despite numerous attempts to dialyze in a variety of refolding buffers, would only yield
~6 - 8% of native, biologically active INS-RTB protein. Therefore, the INS-RTB genes
were introduced into the genome of potato plants by Agrobacterium tumefaciensmediated transformation for the generation of a properly folded, post-translationally
modified source of INS-RTB fusion protein characteristic of a eukaryotic production
system. Synthesis of the INS-RTB protein was confirmed by tissue immunoprint and
Western blot using antibodies that bind INS and RTB. Lectin activity of natively folded
RTB fusion protein was determined by binding to asialofetuin in an enzyme-linked
immunosorbent assay.

xix

CHAPTER ONE
INTRODUCTION
Type 1 Diabetes
Symptoms and Complications
Type 1 diabetes (T1D), sometimes referred to as insulin-dependent diabetes
mellitus (IDDM), is an autoimmune disorder most often seen in children. Until rather
recently, T1D was formerly known as juvenile onset diabetes until it became clear that
there are a significant number of cases where adults with insulin insufficiency were
misdiagnosed as having type 2 (insulin unresponsive) diabetes. Although the causative
mechanisms that lead to the various types of diabetes are different, all forms of diabetes
result in elevated blood glucose levels. Symptoms are shared among different types of
diabetics, but are usually most severe in patients with T1D since they generally endure
fluctuating blood sugar levels for a longer period of their lives. Early indications of T1D
onset include the presence of autoantibodies and T cells that recognize pancreatic selfantigens such as insulin—INS (Palmer, J.P. et al, 1983), glutamic acid decarboxylase—
GAD (Baekkeskov, S. et al, 1990), insulinoma associated autoantigen-2 (IA-2 and IA2|3/phogrin) (Bonifacio, E. et al, 1995; Lu, J. et al, 1996), carboxypeptidase-H (Castano,
L. et al, 1991), islet cell autoantigen-69—ICA69 (Pietropaolo, M. et al, 1993), GM
gangliosides (Nayak, R.C. et al, 1985), imogen-38 (Arden, S.D. et al, 1996), sex
determining region Y-related protein-13—SOX 13 (Kasimiotis, H. et al, 2000), and the
zinc transporter-8 (ZnT8) cation efflux protein (Wenzlau, J.M. et al, 2007).
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The early innate immune system plays an important role in the instigation of an
inflammatory insult to the pancreas, which may prime and sustain the immune system for
a full assault towards the insulin-producing (3-cells (Eizirik, D.L. et al., 2009). The
hormone insulin is required by most cells of the body to trigger their insulin receptors by
eliciting a cascade of intracellular events that ultimately facilitates the uptake and
utilization of glucose from the bloodstream. As (3-cells in the pancreas become
progressively destroyed, more prominent symptoms arise due to the accumulation of
blood glucose that fails to be taken up by cells. Symptoms of hyperglycemia (high blood
sugar) include frequent thirst and urination as the kidneys cope with having to eliminate
excess sugar from the bloodstream. In addition, extreme hunger, weight loss, fatigue, and
blurred vision may occur due to cellular glucose deprivation. Long-term complications
caused by chronic elevation of blood glucose are multifaceted and severe. Statistics on
diabetes complications in the United States have been compiled by the National Institute
of Diabetes and Digestive and Kidney Diseases—NIDDK (National Diabetes Statistics
fact sheet, 2008) and are summarized in Table 1.

Incidence and Prevalence
According to the NIDDK, about 5-10% of diagnosed cases of diabetes are type
1 (autoimmune). There are an estimated 65,000 newly diagnosed cases of T1D
worldwide per year for children under 15 years of age (source: international diabetes
federation). Over the past 50 years, T1D prevalence has been on the rise, which has
seemingly more to due with environmental factors than genetic causation (Gillespie,
K.M. et al, 2004). In a large, multicenter prospective study based on current statistics of
T1D tracked in 17 European countries, the outlook for new cases is grim. It is predicted
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that between 2005 and 2020, the incidence of new T1D cases in European children
younger than five will double, while the prevalence in children under fifteen is expected
to rise by 70% to 160,000 cases (Patterson, C.C. et al., 2009). Worldwide, the agestandardized incidence of T1D in children under 14 has increased in all continents except
Central America and the West Indies from 1990 - 1999 (The DIAMOND Group, 2006).
In this study of 43,013 cases of T1D out of a population size of 84 million (representing
114 populations in 57 countries), the average rise in incidence from 1990 to 1994 was
2.4%. From 1995 to 1999 the worldwide incidence rose to 3.4%. One of the countries
with the highest incidence of T1D is Finland (40.9 per 100,000/year), which only
receives a few hours of sunlight during winter months. Vitamin D is normally produced
by ultraviolet light exposure to the skin. Interestingly, when Finnish children were
supplemented with 2,000 IU of vitamin D during infancy, an 80% reduction in the risk
for developing T1D was observed (Hypponen, E. et al, 2001). This study also revealed
that children with suspected rickets (a bone disease caused by vitamin D deficiency)
during the first year of life had a three-fold increase in the risk of developing T1D later in
life. Based on the worldwide incidence data of T1D (Figure 1), one hypothesis for the
rise in disease cases is that a correlation may exist with populations living at polar
latitudes where the winter season does not afford sufficient atmospheric ultraviolet light
penetration for epidermal vitamin D synthesis. Moreover, people living in increasingly
industrialized nations are more likely to spend time indoors, which can lead to a vitamin
D deficiency. Research is being done to understand the role that natural production or
supplementation of vitamin D plays in autoimmune resistance and treatment (discussed in
the next section). The global variation of T1D prevalence and incidence is likely
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multifactorial and complex, which may involve population genetics, geographic location,
season of birth, clothing styles, sunscreen use, skin color (melanin density), diet (e.g.
vitamin D supplementation, consumption of cow’s milk, nitrates, etc.), socioeconomic
factors, and exposure to pathogens.

Etiology of Type 1 Diabetes
Despite extensive research into the events that trigger autoimmunity and
associated susceptibility factors, significant gaps in the knowledge of immunologic
mechanisms leading to autoimmune diseases remain. The use of experimental animal
models of autoimmune diseases and extensive gene mapping in families with a history of
autoimmunity has helped to elucidate some of the complex immune reactions involved in
the loss of self-tolerance. Several hypotheses regarding autoimmune susceptibility have
arisen from these studies that continue to gain support.

Genetic Determinants
Some individuals have increased susceptibility to autoimmunity because of
haplotype differences in the major histocompatibility complex (MHC) genes that result in
self-antigen presentation to the immune system. In T1D, variations in the HLA-DQ beta
genes determine disease susceptibility, while additional alleles incur significant resistance
to T1D (Todd, J.A. et al, 1987). More recently, a genome-wide search for alleles that
increase risk of T1D development identified 41 loci, including variations in several
important interleukins (IL) genes and surface markers involved in immune activity or (3cell function such as IL10, IL19, IL20, GLIS3, CD69 and IL27 (Barrett, J.C. et al.
2009).
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While not necessarily heritable, the random genetic recombination of T-cell
receptor (TCR) genes that enables the T-cell to recognize an almost limitless array of
antigenic epitopes, can result in TCRs that bind to self-peptides. Normally, these
autoreactive T-cells are screened for in the thymus (thymic selection). However, there is
evidence that some of these autoimmune-capable T-cells may escape selection and are
suppressed in the periphery of healthy individuals by means of the regulatory immune
system as a backup safety mechanism. In autoimmune victims, the regulatory system
fails to downregulate these autoreactive T-cells. A compilation of the predominant
known epitopes recognized by CD4 and CDS T-cells from humans and mice with
autoimmune (type 1) diabetes has been published by Di Lorenzo, T.P. et al. (2007). The
majority of the epitopes are fragments of proinsulin (INS), isoforms of glutamic acid
decarboxylase (GAD65 and GAD67), heat shock protein (HSP60 and HSP70),
insulinoma-associated protein 2 (IA-2 and IA-2P), islet cell autoantigen (ICA69 and
ICA512), and islet-specific glucose-6-phosphatase catalytic subunit-related protein
(IGRP). Another autoantigen recently identified in T1D patients is the zinc transporter
protein—ZnTS. Autoantibodies to ZnTS were found in 60 - 80% of patients with new
onset T1D, including 26% that uniquely had ZnTS antibodies in the absence of antibodies
that recognize the usual markers of |3-cell autoimmunity—INS, GAD, IA-2, and ICA
(Wenzlau, J.M. et al, 2007). Detection of T1D at disease onset was achieved in 98% of
individuals when antibodies were screened against INS, GAD, IA-1, and ZnTS
combined.
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Molecular Mimicry
Because genetics alone only accounts for less than half of the cases of T1D, there
must also exist environmental influences on disease instigation (Drescher, K.M. and
Tracy, S.M., 2008). There is increasing evidence that people may be at risk of
developing an autoimmune disease simply through exposure to certain pathogens,
although this concept has not yet been clearly determined. Molecular mimicry, epitope
spreading, and direct bystander activation by pathogen epitopes with similar structure or
binding capacity to human proteins can lead to cross-reactive antibody or T-cell receptor
formation that can trigger an immune attack against self-tissues (Olson, J.K. et al., 2001).
At least 14 different viruses have been reported thus far that may cause or lead to T1D in
humans and various animal models (Jun, H.S. and Yoon, J.W., 2003). One of the viruses
most suspected of eliciting a cross-reactive immune response is the Coxsackie B virus
(Drescher, K.M. and Tracy, S.M., 2008). However, other reports demonstrate that in
some cases, molecular mimicry by pathogen proteins may not directly lead to
autoimmune disease and that additional mechanisms leading to perpetuation of
immunopathogenesis must also be involved (Davies, J.M., 1997; Cainelli, F. et al, 2000;
Benoist, C. and Mathis, D., 2001; Schloot, N.C. et al, 2001). For a recent review of the
role that viruses and bacteria play on the instigation of T1D and other autoimmune
diseases, see Cooke, A. (2009a).

Consumption ofCow’s Milk
Several lines of evidence provide support for the association of T1D and early
introduction of cow’s milk (reviewed in Peng, H. and Hagopian, W., 2006; Rosenbauer,
J. et al, 2008). Immunological evidence includes the presence of antibodies in patients
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with T1D that recognize bovine serum albumin, (3-casein (Monetini, L. et al., 2002), and
cow’s milk protein in general (Luopajarvi, K. et al, 2008). Further, T-cells have been
identified in type 1 diabetics that bind to epitopes of bovine (3-casein (Monetini, L. et al,
2003) as well as lymphocytes that recognize bovine (3-lactoglobulin (Vaarala, O. et al.
1996). The bovine insulin present in cow’s milk has also been implicated in triggering
autoimmunity towards human insulin through molecular mimicry (Paronen, J. et al.
2000). However, cow’s milk is unlikely to be the sole cause of T1D, which more
realistically involves a combination of genetic and/or environmental factors that may or
may not be connected with cow’s milk (Merriman, T.R., 2009).

Probiotics and Commensal Organisms
One of the extraordinary and baffling tasks of the gut mucosal immune system is
the ability to distinguish beneficial foreign substances (e.g. food particles and the vast
flora of health-promoting microorganisms) from potentially dangerous compounds or
pathogens. The great majority of known bacteria (>300,000 species to date) are either
harmless or beneficial in nature, with only 170 species that are known to be pathogenic to
mammals (McBride, S.W. and Mazmanian, S.K., 2009). Other than the role of beneficial
microbes to outcompete pathogens and assist in the breakdown of food for production of
vitamins/nutrients in our digestive tract, another positive role may be the ability to
maintain immune homeostasis.
One theory that may help explain the rise of T1D and other disorders of a hypervigilant immune system is the “hygiene hypothesis”. This was first proposed by David P.
Strachan as a possible reason for the increase in allergies, asthma, and childhood eczema
among affluent populations or industrialized nations (Strachan, D.P., 1989). The theory
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postulates that because the last century has seen a decline of family size, improvements in
household amenities/cleaning supplies, and higher standards of personal cleanliness, this
has resulted in less exposure to environmental antigens or contagious diseases during
childhood that would otherwise “train” the immune system to behave normally. The
proposed mechanism is that normal development of the immune system requires
antigenic stimuli (from infectious agents, symbiotic bacteria, or parasites) in order to
properly stimulate regulatory T-cells. Otherwise a person may be more susceptible to
autoimmune and allergic diseases caused by insufficiently repressed Thl and Th2
responses, respectively (Bufford, J.D. and Gem, J.E., 2005). Certain organisms are
known to stimulate regulatory T-cells—Tregs (Rook, G.A. et al., 2004), perhaps as a way
of evading immune destmction. Some of the organisms that may be important for proper
development of Trcgs capable of suppressing effector T-cells (Teff) include lactobacilli,
various mycobacteria, and certain helminthes (Rook, G.A. and Bmnet, L.R., 2005).
Should a legitimate threat appear to the host immune system, the “danger signal” from
activated Toll-like receptors can downregulate Tregs and re-enable effector functions
(Pasare, C. and Medzhitov, R., 2003).
The therapeutic potential of using immunomodulating bacterial species or isolated
cell-wall components for disease suppression has been demonstrated in the mouse model
of inflammatory bowel disease—IBD (Mazmanian, S.K. et al, 2008). Wild-type mice
were first colonized with the protective bacteria Bacteroides fragilis, which possesses a
coat of polysaccharide A (PSA) known to direct the cellular and physical maturation of
the developing immune system (Mazmanian, S.K. et al, 2005). Next, the mice were
inoculated with Helicobacter hepaticus—a bacterial species that has been shown to
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initiate IBD. The H. hepaticus infection activated Thl7 cells in the gut, which produced
proinflammatory cytokines such as IL-17, IL-23, and tumor necrosis factor alpha (TNFa). Dendritic cells (DCs) of mice that were colonized with B.fragilis took up the PSA
and presented it on the surface. This resulted in the activation of Tregs, which then
secreted IL-10 to quench the inflammation caused by IL-17 producing cells. B.fragilis
mutants lacking PSA did not suppress inflammation in the IBD model, while the addition
of purified PSA did, indicating that PSA is the causative agent for immunoregulation.
Other examples of organisms used in the suppression of immune diseases include the
therapeutic introduction of helminth nematodes in the gut to inhibit T1D in non-obese
diabetic (NOD) mice as an experimental model (Cooke, A., 2009b).
Lactobacillus casei is another bacterium that has recently been used as a probiotic
for the enhanced induction of oral tolerance of an autoimmune disease. In the murine
model of rheumatoid arthritis (RA), a team of South Korean scientists found that co
administration of L. casei with Type II collagen—an RA autoantigen, improved the
disease suppression capacity compared to either the bacteria or autoantigen alone (So,
J.S. et al, 2008). The mixture significantly potentiated the suppression of arthritic
inflammation and damage to cartilage tissue by stimulating Foxp3+CD4+ T-cells that
suppressed Thl cell function. This was accompanied by a reduction of proinflammatory
cytokines (IL-1|3, IL-2, IL-6, IL-12, IL-17, IFN-y and TNF-a) and an increase in anti
inflammatory cytokines (IL-10 and TGF-|3).
The updated theory behind the hygiene hypothesis is that the rise in autoimmunity
and allergies may have more to do with not having the appropriate beneficial colonizers
of human mucosal sites, more so than the presence or absence of pathogenic strains. A
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healthy flora may contain species that maintain homeostasis or skew the mucosal immune
system environment towards a regulatory/suppressive mode. On the other hand,
pathogens and other environmental triggers might initiate a domino effect of
inflammation that leads to self-reactivity. Since microorganisms must compete for
location and food at mucosal sites, it may be imperative that helpful species prevail over
harmful ones. This is particularly problematic after a course of antibiotics that “clean the
slate” for new and potentially dangerous microbes to settle in. Perhaps the protective
benefits of a healthy flora might explain why some animals such as elephants feed their
newborns an appetizer of partially digested feces as a natural source of probiotics.

Vitamin D Deficiency
Inadequate levels of vitamin D are reported in approximately 36% of the U.S.
young adult population and up to 57% of general inpatients (Holick, M.F., 2006). Serum
concentrations of vitamin D vary in other countries, but there is a global trend in
insufficiency (Prentice, A., 2008). In France, about 14% of adults have low vitamin D
levels (Chapuy, M.C. et al., 1997), while over 90% of women of child-bearing age in
Beijing and Hong Kong have a vitamin D insufficiency (< 50 nmol/1) (Woo, J. et al,
2008). Also startling was that 40% of the Beijing women and 18% of the Hong Kong
women exhibited a vitamin D deficiency (< 25 nmol/1).
People with T1D, cancer, or hypertension typically have low serum levels of
vitamin D (Melamed, M.L. et al, 2008). When supplemented with 300 - 2,000 IU of
vitamin D, human subjects often have lower rates of autoimmune disease and markers of
inflammation (Autier, P. and Gandini, S., 2007). An interesting correlation is seen with
people living at polar geographic locations and the prevalence of diseases associated with
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vitamin D deficiency, including certain cancer types, muscular weakness, hypertension,
autoimmune diseases, multiple sclerosis, schizophrenia, and depression (reviewed in
Huotari, A. and Herzig, K.H., 2008). Presumably, this is because areas further away
from the equator receive less ultraviolet solar radiation during the winter months and
therefore produce less vitamin D. In addition, people tend to stay indoors during the cold
winter months and are heavily clothed when they venture outside. Indeed, a comparison
of 51 regions worldwide indicate an association with reduced ultraviolet-B radiation and
increased incidence of T1D after controlling for per capita health expenditure and cloud
cover (Mohr, S.B. et al., 2008). However, the reduced ultraviolet radiation in winter
months only seems to be a factor at locations >25° N and is influenced by ozone
fluctuations and air pollution (Kimlin, M.G. et al, 2007).
For at least 25 years, vitamin D has been known to have immunomodulating
effects (Lemire, J.M. et al, 1984; Rigby, W.F. et al, 1984), in addition to its well-known
role in regulating calcium and phosphorous levels in the body. All forms of vitamin D in
nature require ultraviolet radiation from the sun for part of the biosynthetic process.
Plants and fungi synthesize vitamin D2 (ergosterol). Animals generate vitamin D3
(cholecalciferol) predominantly in the skin and eyes when exposed to ultraviolet B
radiation. Fish ultimately obtain vitamin D from the consumption of photosynthetic
algae, while fur- or feather-bearing animals get a significant amount of the D vitamin
from oily skin secretions exposed to sunlight, which is then orally absorbed by grooming
or preening (Uva, B. et al, 1983; Carpenter, K.J. and Zhao, L., 1999; Albert, P.J. et al,
2009). Both D2 and D3 are converted into the active form of the hormone 1,25dihydroxyvitamin D3 (1,25-D) in the liver (Albert, P.J. et al, 2009). The vitamin D
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metabolite 1,25-D (also known as calcitriol) binds to the vitamin D receptor (VDR),
which is expressed on numerous cell types. These include immune cells such as
macrophages, dendritic cells, and activated T- or B-lymphocytes, which are all also
capable of producing the enzyme that converts vitamin D into calcitriol (Bikle, D.D.,
2009). VDR activation results in the transcription of at least 913 genes (Wang, T.T. et
al., 2005), several of which are involved in bactericidal actions and both innate and
adaptive immune functions (Zasloff, M., 2002; Albert, P.J. et al, 2009; Bikle, D.D.,
2009). However, in the mouse model of T1D, non-obese diabetic (NOD) mice that lack
VDR still develop diabetes symptoms (Gysemans, C. et al, 2008). Yet NOD mice given
vitamin D or a non-hypercalcemic analog have shown disease prevention and protection
(Mathieu, C. et al, 1994; Casteels, K.M. et al, 1998; Gregori, S. et al, 2002; Zella, J.B.
et al, 2003; Driver, J.P. et al, 2008). In addition, T1D is accelerated in NOD mice that
were vitamin D deficient early in life (Giulietti, A. et al, 2004). NOD mice given 5
p,g/kg calcitriol (1,25-D3) every other day were significantly prevented from developing
diabetes compared to controls (Mathieu, C. et al, 1994). The supplemented mice
developed suppressor T-lymphocytes that could prevent diabetes in irradiated recipient
mice in an adoptive transfer experiment. The T1D model in rats has also shown mildly
protective effects upon treatment with a vitamin D analog (Pedulla, M. et al, 2007).
The active form of vitamin D3 also seems to protect the insulin-producing |3-cells
in the pancreas of NOD mice by decreasing expression of chemokines and cytokines in
these cells (Gysemans, C.A. et al, 2005). Human |3-cells are protected by vitamin D3
through the downregulation of Fas ligand, which inhibits cytokine-mediated apoptosis
(Riachy, R. et al, 2006). These findings suggest a more complicated role for vitamin D
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in the control of T1D that may or may not involve the VDR. A further confounding
factor is that pancreatic p-cells also express VDRs, and several VDR gene
polymorphisms in humans have been associated with decreased secretion of insulin or
elevated blood glucose seen in both type 1 (Shimada, A. et al, 2008) and type 2
(Palomer, X. et al, 2008) diabetics. Other gene alleles involved in vitamin D signaling
and metabolism associated with T1D development have been reported (Bailey, R. et al.
2007; Ponsonby, A.L. et al, 2008).
The importance of vitamin D for the prevention and treatment of T1D in humans
has been highlighted by several studies. In one form of autoimmune diabetes—latent
autoimmune diabetes in adults (LADA), patients were given a vitamin D analog along
with their usual insulin treatments. These patients had improved survival of pancreatic 13cells over those who were given insulin alone, as measured by the levels of C-peptide (Li,
X. et al, 2009). C-peptide is the portion of the insulin precursor proinsulin, which is
enzymatically cleaved out to yield the active form of the insulin hormone. Since
exogenous insulin injections do not contain the C-peptide, the presence of this excised
peptide in the blood is an indicator of newly synthesized insulin by |3-cells. In a
Norwegian case-control study of childhood T1D, researchers tracked the intake of codliver oil, a rich source of vitamin D, by infants during the first year of life and found a
significantly lowered risk of developing T1D (Stene, L.C. and Joner, G., 2003).
However, the authors suspect that some of the lowered disease risk could have been
attributed to the protective effects of the omega-3 fatty acids eicosapentaenoic acid and
docosahexaenoic acid present in the fish oil. A European study has further confirmed the
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reduced risk of T1D in infants that were given supplemental vitamin D (The EURODIAB
Substudy 2 Study Group, 1999).
Progress is being made on the molecular mechanisms that might account for the
actions of vitamin D on immune regulation, particularly on the prevention of T1D and
other autoimmune disorders. The active form of vitamin D3 (calcitriol) has been shown
to inhibit the production of interferon gamma (IFN-y), interleukin-2 (IL-2) and IL-12
(Lemire, J.M., 1995), which are important proinflammatory cytokines involved in the
pathogenesis of T1D (discussed in latter sections). Further, calcitriol prevents the
differentiation, maturation, and function of dendritic cells (DCs), disabling their ability to
secrete IL-12 and activate any T-cells that could cause autoimmune destruction
(Piemonti, L. et al., 2000). Tolerogenic DCs induced by vitamin D receptor ligands have
decreased expression of costimulatory molecules CD40, CD80, and CD86, with a
concomitant decrease in IL-12 production and increased IL-10 secretion typical of an
immunoprotective response (Adorini, L., 2003). These suppressor DCs were shown to
activate regulatory T-cells (TregS) that express CD40 and CD25, which are able to inhibit
the T-cell response to a pancreatic autoantigen and to significantly delay disease transfer
by pathogenic Thl cells. The complex mechanisms involved with vitamin D and its
analogs on dendritic cell tolerogenicity has recently been reviewed by Adorini and Penna
(2009).
Of particular relevance to this dissertation proposal, researchers have recently
discovered that the activation of certain Toll-like receptors (TLRs) on DCs by TLR
ligands or vaccine antigens can initiate the metabolism of vitamin D into its active
form—calcitriol, which in turn enhances the mucosal immune response (Enioutina, E.Y.
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et al, 2008, 2009). TLRs are molecules on cells of the innate immune system that
recognize general pathogen-associated molecular patterns (PAMPs) common to many
components of pathogens and toxins. Some TLRs may also induce immune tolerance
upon activation by certain PAMPs (Liang, S. et al., 2007; Vaknin, I. et al, 2008). All
known receptors of the TLR family are expressed by the islet cells of mice and humans,
and when engaged by pathogen-derived ligands, the islet TLRs upregulate
proinflammatory chemokine production (Giarratana, N. et al, 2004). When given a
vitamin D analog however, the proinflammatory chemokine production by islet cells was
significantly downregulated both in vitro and in vivo (Giarratana, N. et al, 2004). This
inhibited T-cell recruitment into the pancreatic islets and blocked subsequent
development of T1D even after re-stimulation with TLR ligands.
As discussed later in this work, the use of toxin B subunits as potential sources of
PAMPs for enhanced immune reactivity may have a connection with the synthesis of
calcitriol by DCs. The localized production of calcitriol by tolerogenic DCs favors
regulatory T-cell activation and decreased production of proinflammatory chemokines by
islet cells. This might explain the reduction of T1D when toxin B subunits are co
delivered as fusion proteins to autoantigens. Immune tolerance to autoantigens by
themselves is also improved when vitamin D is co-administered. A shift in the cytokine
secretion profile from a pathogenic Thl cell response to a tolerogenic Th2 cell response
in the pancreas of NOD mice is enhanced by injection of the diabetes autoantigen
glutamic acid decarboxylase (GAD) in mice given vitamin D (Overbergh, L. et al, 2000).
Re-challenge of the mice with GAD and other autoantigens (heat shock protein 65 and
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insulin B-chain) also established a cytokine profile that favored Th2 activity in the
pancreas and peripheral lymph nodes.
More than 50 years before vitamin D was discovered, the potent health benefits of
sunshine have been known, as indicated by the following passage written in 1870:
“Invalids too often deprive themselves of sunlight. This is one of nature's most healing
agents. It is a very simple, therefore not a fashionable remedy... Our own folly has led
us to deprive ourselves of things that are precious, of blessings which God has provided
and which, if properly used, are of inestimable value for the recovery of health” (White,
E.G., 1885). It has become increasingly clear that one of the primary factors in disease
prevention and treatment that directly relates to sunlight exposure for “heliotherapy” is an
increase in vitamin D biosynthesis.

Cellular Pathogenesis of Type 1 Diabetes
The first indication of disease onset in patients with T1D is the presence of
autoantibodies produced by self-reactive B-cells. Some children manifest autoantibodies
as early as three months of age (Kukko, M. et al, 2005). The likelihood of developing
full-blown disease characterized by chronic high blood sugar (hyperglycemia) is
generally proportional to the quantity and variety of circulating autoantibodies present
(Taplin, C.E. and Barker, J.M., 2008). In T1D patients, the number of autoantibodies to
insulin (INS), glutamic acid decarboxylase (GAD), or islet cell autoantigen-512
(ICA512) is indicative of the relative risk for development of diabetes among first-degree
relatives (Verge, C.F. et al, 1996a; Verge, C.F. et al, 1996b). The five year risk of
diabetes outcome was as follows: No positive autoantibodies = 0%; presence of
autoantibodies to one autoantigen = 15%; two autoantigens = 44%; three autoantigens =
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100% risk. Anti-INS antibodies can be found in 50-70% of T1D children (Greenbaum,
CJ. et al., 1992) and anti-IA-2 antibodies are seen in 70-80% of cases (Gorus, F.K. et al.,
1997). Anti-GAD antibodies occur in 70-75% of T1D patients, but interestingly 1-2% of
the general population have anti-GAD antibodies and retain normal pancreatic function
(Sanjeevi, C.B. et al, 1996). This suggests that autoreactive lymphocytes may be present
in healthy individuals, but are down-regulated by tolerogenic mechanisms after they
escape thymic selection early in life.
Disease onset due to hyperglycemia (>250 mg/dl blood glucose) can take years to
develop after the initial presence of autoantibodies (Eisenbarth, G.S., 1986). While
autoantibodies produced by B-cells are indicative of disease onset, they are not thought to
serve a pathogenic role (Yoon, J.W. and Jun, H.S., 2005). The main role of B-cells in
cellular destruction may have more to do with their ability to present |3-cell antigens to
autoreactive T-cells, which in turn trigger cytotoxic lymphocytes to destroy the |3-cells
directly. Hyperglycemia, the clinical symptom of overt diabetes, only occurs after >8090% of the insulin-producing |3-cells have been destroyed by cytotoxic T-lymphocytes
and macrophages (Knip, M. and Siljander, H., 2008). Although |3-cell destruction
persists throughout the lifetime of a person with T1D, it appears that these insulinproducing cells continue to be generated in the pancreas and can still be found in >88%
of patients who have the disease (Meier, J.J. et al, 2005). This suggests that if a targeted
immune suppression therapy such as the one proposed in this dissertation were applied,
newly formed (3-cells would be protected from autoimmune destruction until
normoglycemia could be restored. Alternatively, stem-cell therapy may supplement and
accelerate the regeneration of islets, but only if autoreactive lymphocyte activity is

17

curtailed to avoid destruction of nascent (3-cells. The primary lymphocytes involved in 13cell destruction that would need to be down-regulated or eliminated in order for
pancreatic function to be restored are here described (see also Figure 3 and Appendix E):

Dend?itic cells (DC)
DCs, in addition to B-cells and macrophages, make up the professional antigen
presenting cells (APC) of the immune system. The key upstream components that
determine the immunological outcome of T-cells are thought to be the maturity status of
dendritic cells (DCs) and the cytokine environment (Tan, J.K. and O'Neill, H.C., 2005).
In the presence of interleukin-12 (IL-12) and antigen, DCs commit to an inflammatory
response and trigger nai've CD4+ ThO cells to proliferate and differentiate into T helper 1
(Thl) cells (Macatonia, S.E. et al., 1995) or T-follicular helper (Thf) cells (Schmitt, N. et
al., 2009). IL-10 on the other hand, influences the DC to activate T helper 2 (Th2) cells
and other regulatory cells for immune suppression (discussed in the next section). The
detailed mechanisms that determine whether a DC will activate an inflammatory (Thlmediated) response or an immunosuppressive response have not been fully elucidated.
Exogenous administration of IL-10 or the use of antibodies that neutralize IL-12 are two
options being explored as potential therapies to skew DCs in favor of immunosuppression
for the treatment of T1D (Fujihira, K. et al, 2000; Slavin, A.J. et al, 2001; Denes, B. et
al, 2006).

Macrophages (M(pj
Macrophages play two major roles in the destruction of |3-cells. The first is to
pick up and present (3-cell specific autoantigens to activate Thl cells with matching
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receptors. These autoreactive Thl cells then release interferon gamma (IFN-y) that
activate other macrophages to become cytotoxic. The cytotoxic macrophages migrate to
the pancreas and specifically kill (3-cells through the actions of inflammatory cytokines
(IL-1|3, TNF-a, and IFN-y) and free radicals (O2’, H2O2, and NO) (Yoon, J.W. et al.
1998).

Cytotoxic T-iymphocytes (CTL)
CD8+ CTLs are the most abundant inflammatory cells found in the pancreas at
the time of insulitis (the infiltration of islets by immune cells) (Willcox, A. et al, 2009).
Normally, CTLs that recognize self-antigens are screened in the thymus, bone marrow, or
periphery by APCs and eliminated. However, abnormal CTL education due to receptor
dysfunctions between the APC and the CTL can result in the circulation of autoreactive
CTLs (Faustman, D.L. and Davis, M., 2009). (3-cell antigen-specific CTLs become
cytotoxic after initiation by IL-2 from effector (diabetogenic) Thl cells (Yoon, J.W. and
Jun, H.S., 2005). The activated CTLs migrate to the islets of Langerhans and trigger
apoptosis through interaction of the Fas ligands (FasL) on CTLs, which bind to Fas on (3cells (Su, X. et al, 2000). In addition, CTLs release perforin (cytolysin) that “punches
holes” in the membrane of (3-cells and then granzymes are poured in to enzymatically
destroy the cells (Young, L.H. et al, 1989; Estella, E. et al, 2006).

Natural killer (NKJ cells
NK cells are capable of directly killing target cells to control malignancies and
virus-infected cells without requiring previous “activation” by APCs, hence they are an
important first line of innate defense for the rapid destruction of cells (Colucci, F. et al,
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2003). Like CTLs, NK cells induce apoptosis of target cells by releasing perforin and
granzyme, plus they also secrete inflammatory cytokines such as IFN-y, TNF-a,
granulocyte-macrophage colony-stimulating factor (GM-CSF), and macrophage
inflammatory protein (MIP) la and 1(3 (Backstrom, E. et al., 2004). In addition to
attacking cells with abnormal presentation of cell surface components (e.g. viral coat
proteins), NK cells an also have inhibitory functions depending on which receptors are
activated (Moretta, A. et al, 2000). In this sense, they behave as NKT regulatory cells in
suppressing disease (NKT cells are described in Table 2).
Since NK cells can interact with APCs, they have the potential to interfere in the
priming of autoimmune responses, either by promoting autoreactive B- and T-cell
proliferation, or by eliminating these cells (French, A.R. and Yokoyama, W.M., 2004).
In addition, the heavy destruction of virus-infected autologous cells may trigger the
release of self-antigens in an inflammatory environment where autoimmunity is more
likely to develop (Rodacki, M. et al, 2006).
Thelper J (ThJJ cells
T-lymphocytes that inadvertently recognize (3-cell autoantigens and are not
eliminated or suppressed by the immune system can become activated upon binding to
antigen presenting cells (APCs). APCs display fragments of autoantigens on major
histocompatibility complex-II (MHC-II) surface molecules, along with co-stimulatory
molecules that interact with matching T-cell receptors (TCR). Depending on the cell
environmental conditions such as antigen concentration, presence/absence of
immunomodulators, or the particular cytokine profile, an APC can either activate a T-cell
or alternatively, make the T-cell non-responsive (anergic) (Fowler, E. and Weiner, H.L
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1997). NaiVe T-helper cells (ThO) that are activated by APCs through cytokine
stimulation and receptor docking can differentiate into Thl or Thl7 cells to mediate
cytotoxic activities (Ichinose, K. et al., 2007). The secretion of IL-2 and IFN-y by Thl
cells has dual functions: 1.) Activation of cytotoxic macrophages and CTLs, 2.)
Downregulate Th2 cell activity (Yoon, J.W. and Jun, H.S., 2001; Crane, I.J. and
Forrester, J.V., 2005).

IL-J7producing ceils (Thl7 and Tc17)
CD4+ Thl7 cells and CD8+ Tcl7 cells are two recently described T lymphocytes
that are mainly characterized on the basis of their ability to produce the proinflammatory
cytokine IL-17. Thl 7 cells constitute a third group of effector T lymphocytes (in
addition to Thl and Th2 cells) that are associated with autoimmunity (Harrington, L.E. et
al, 2005). In addition to the production of IL-17, IL-21, and IL-22 (Bettelli, E. et al,
2007), Thl 7 cells are also distinguished by their expression of the transcription factor
retinoic acid orphan receptor gamma—ROR-yt (Ivanov, II et al, 2006). Thl7 cells are
generated when naive CD4+ T cells are exposed to TGF-|3 and IL-21, or when central
memory CD4+ T cells encounter IL-1|3 and IL-6 (Acosta-Rodriguez, E.V. et al, 2007;
Manel, N. et al, 2008; Volpe, E. et al, 2008; Yang, L. et al, 2008). Thl7 cells normally
function to control extracellular pathogens, but they also play an important role in human
and experimental autoimmunity (Bettelli, E. et al, 2007). Transfer of islet-specific Thl 7
cells to NOD mice resulted in diabetes induction, but only after the cells had converted to
IFN-y-producing cells (Bending, D. et al, 2009; Martin-Orozco, N. et al, 2009). The
inhibition of Thl 7 cells, either with neutralizing anti-IL-17 or with recombinant IL-25,
has been shown to influence the course of diabetes in NOD mice (Emamaullee, J.A. et
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al, 2009). Monocytes isolated from the blood of T1D patients were found to
spontaneously secrete the proinflammatory cytokines IL-1|3 and IL-6, which are known
to induce and expand Thl7 cells (Bradshaw, E.M. et al, 2009). However, Thl7 cells do
not seem to be independently responsible for autoimmunity in general. Thl cells can
induce disease in the absence of Thl 7 cells, but Thl 7 cells are not sufficient to induce
disease in the absence of Thl cells (Chitnis, T. et al, 2001; Bettelli, E. et al, 2004).
Recently, it was discovered that Thl7 cells also generate large amounts of IL-9, a
cytokine normally produced by Th2 and associated with suppressive functions (Elyaman,
W. et al, 2009). To add to the confusion, IL-17 has been shown to have a protective
effect in T-cell mediated intestinal inflammation (O'Connor, W., Jr. et al, 2009).
Tcl7 cells can also produce IL-17 and usually release IFN-y as well (Kondo, T. et
al, 2009). They can become diabetogenic if exposed to IL-23 (Ciric, B. et al, 2009), but
normally function in the clearance of viral infection (Hamada, H. et al, 2009). Little else
is known about these recently described cells.

The/per 9 cells (Th9)
Th2 cells, which are normally involved in B-cell activation and immune
regulatory functions, can be coaxed into secreting IL-9 in the presence of TGF-|3 or they
can drive the differentiation into Th9 cells directly through IL-4 interaction (Veldhoen,
M. et al, 2008). Th9 cells also produce the suppressor cytokine IL-10, but were shown
to lack regulatory properties and instead promote tissue inflammation (Dardalhon, V. et
al, 2008). In adoptive transfer experiments using an animal model of multiple sclerosis,
Thl, Th9, and Thl7 cells were all able to promote autoimmunity, although the
pathological outcomes for each cell differed (Jager, A. et al, 2009).
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Tfollicular helper cells (Tfh)
The follicles of lymph nodes are important sites for the education of humoral
immune responses. One type of recently discovered helper cell that aids in the activation
of B-cells in the germinal center of nodes is the Tfh cell. These cells develop from naive
CD4+ T lymphocytes in the presence of IL-21 but not TGF-|3 signaling and are
independent of Thl, Th2, and Thl7 cell lineages (Nurieva, R.I. et al, 2008; Vogelzang,
A. et al, 2008). Instead, Tfh cells appear to originate from suppressive CD4+FoxP3+
cells that undergo a loss of FoxP3 expression and subsequently interact with B-cells, as
demonstrated in the Peyer’s patches of the mouse intestine (Tsuji, M. et al, 2009). Tfh
cells might also participate as inhibitors of Thl cell differentiation, since Tfh, Th2, and
Thl7 cells can all make IL-21 (Corthay, A., 2009). The over- or under- expression of
Tfh cell-associated molecules may contribute to the pathogenesis of certain autoimmune
diseases or immunodeficiencies (King, C. et al, 2008).

Oral Tolerance Therapy for Autoimmune Diseases
Current Understanding of Oral Tolerance Mechanisms
Immune tolerance is a vital aspect of the gut-associated lymphoid tissue (GALT)
with two primary roles: 1.) It permits the presence of beneficial foreign compounds such
as food and commensal bacteria. 2.) It tames the repercussions of a heated battle against
pathogens to restrain superfluous tissue damage. Thus, the GALT acts as a “security
guard” at the checkpoint of the interface between environment and host. All the identity
badges of foreign substances are examined—the sequences that bear danger signals in the
form of pathogen-associated molecular patterns (PAMPs) are rejected; the friendly
signals are identified but tolerated. Although dietary proteins and beneficial
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microorganisms do not generally induce an inflammatory response, recognition by Th2
cells and the subsequent training of B-cells to secrete neutralizing IgA antibodies can
occur. However, this secretory IgA formation may not be necessary or relevant to
immune tolerance (Challacombe, S.J. and Tomasi, T.B., Jr., 1980; Fuller, K.A. et al,
1990).
The same system responsible for natural tolerance can also be exploited to
generate an immunosuppressive response towards fed autoantigens. Two primary forms
of oral tolerance can be induced—“active suppression” mediated by low doses of antigen,
or inactivation (“anergy”) of autoreactive T-lymphocytes by high antigen doses (Mowat,
A.M. et al, 1982; Friedman, A. and Weiner, H.L., 1994).
Active suppression involves the generation of antigen-specific regulatory cells
that are trained by antigen-presenting cells (APCs) in the GALT. The immunoregulatory
cells that play a role in oral tolerance identified so far include: Th2, Th3, Trl,
CD4+CD25+ T (more appropriately called FoxP3 cells since CD25 is not a unique marker
of this class of immunosuppressive cells), CD4+CD45RB low , and CD4+LAP+ T-cells.
The known function of these cells will be explained in the next section.
Inactivation of inflammatory T-cells is achieved through anergy (clonal
unresponsiveness) or by clonal deletion when large antigen doses are fed. Anergic Tcells are not totally passive and can even produce immune-suppressing cytokines such as
IL-4 and IL-10 (Lanoue, A. et al, 1997; Buer, J. et al, 1998; Ryan, K.R. and Evavold,
B.D., 1998). CD4+ T-cells that are anergic have shown suppressor activity both in vivo
and in vitro (Hirahara, K. et al., 1995; Taams, L.S. et al., 1998; Takahashi, T. et al..
1998). Clonal deletion occurs by apoptosis, which is cleaned up by dendritic cells
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(Huang, F.P. et al., 2000) and macrophages that phagocytose the dying cells, resulting in
the downregulation of pro-inflammatory cytokines and the induction of transforming
growth factor beta (TGF-|3) production (Freire-de-Lima, C.G. et al, 2000). The
apoptotic T-cells themselves can also release TGF-(3 both in latent and bio-active form
(Chen, W. et al, 2001). The release of TGF-p during apoptosis and engulfment by
antigen presenting cells may result in the induction of regulatory T-cells at mucosal sites,
since this growth factor initiates the generation of Th3 cells (Paul, W.E. and Seder, R.A.,
1994; Weiner, H.L., 2001b) and FoxP3+ TregS (Chen, W. et al, 2003).

Role of Regulatory T-cells in Autoimmune Suppression
Th2 ce/Is
These are a subset of CD4+ T-cells that suppress the destructive activity of Thl
CD4+ cells by secreting IL-4 and IL-10, which downregulates the production of IL-2 and
IFN-y by Thl cells (Fishman-Lobell, J. et al, 1994; Weiner, H.L., 1994). Th2 cells are
not the only moderators of oral tolerance, since IL-4 deficient mice lacking Th2 cells can
undergo oral tolerance induction with both low and high doses of antigen (Garside, P. et
al, 1995) or when treated with neutralizing anti-IL-4 antibodies (Wolvers, D.A. et al.
1997). Other subsets of regulatory cells are mentioned below:

ThS cells
These cells are characterized by the secretion of high amounts of TGF-|3 (Faria,
A.M. and Weiner, H.L., 2006). Functions of TGF-|3 as an immunosuppressive cytokine
include the induction of IL-10 for suppression of Thl inflammation and the
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downregulation of IL-12 receptor on T-cells, which decreases their ability to become
activated by APCs for inflammatory responses (Kitani, A. et al., 2000).

Tr/ cells
Another class of differentiated CD4+ T-cells that form in the periphery when they
interact with tolerogenic APCs in the presence of IL-10 are T regulatory 1 cells—Trl
(Roncarolo, M.G. et al, 2006). Trl cells are characterized by the secretion of mainly IL10 in large quantities (Groux, H. et al, 1997). However, there are currently no known
unique surface markers by which Trl cells can be tracked or purified (Allan, S.E. et al.
2008). When stimulated through the T-cell receptor, Trl cells in turn produce IL-10 to
enhance TGF-|3 production by Th3 cells (Weiner, H.L., 2001a). Abnormal differentiation
of Trl cells has been implicated in autoimmune diseases such as multiple sclerosis
(Astier, A.L. and Hafler, D.A., 2007; Ma, A. et al, 2009). The use of autoantigenspecific Trl cells is currently being explored as a complement to p-cell transplantation to
avoid immune rejection in an animal model of T1D (Gagliani, N. et al, 2009).

FoxP3+ T-cells
Forkhead box (Fox) P3 T cells are innate regulatory cells that expand and develop
when induced by TGF-|3 (Chen, W. et al, 2003; Huber, S. et al, 2004). TGF-|3 has been
shown to regulate the in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory Tcells for protection against diabetes (Peng, Y. et al, 2004). CD4+CD25+Foxp3+ cells
suppress innate and adaptive immune responses in experimental models of autoimmunity
such as arthritis, colitis, diabetes, autoimmune encephalomyelitis, lupus, gastritis,
oophoritis, prostatitis, and thyroiditis (reviewed in Suri-Payer, E. and Fritzsching, B.,

26

2006). Mice tolerized by oral administration of ovalbumin showed an increase of
CD4+CD25+ Tregs that expressed cytotoxic T-lymphocyte antigen-4 (CTLA-4) on its
surface for up to 4 weeks after feeding (Zhang, X. et al, 2001). CTLA-4 acts as a
negative regulator of T-cell activation by tying up B7 molecules (Waterhouse, P. et al,
1995). CD4+CD45RBlow T-cells have been shown to suppress colitis and are dependent
on TGF-|3 but not IL-4 (Powrie, F. et al, 1996). CD4+LAP+ T-cells express latencyassociated peptide (LAP). All LAP+ cells are also positive for thrombospondin 1, a
natural converter of latent TGF-|3 to its active form (Oida, T. et al, 2006). A summary of
the various types and roles of immune regulatory cells is given in Table 2.

Oral Tolerance Therapy Trials for Suppression of Experimental
Autoimmune Disease
About 3-5% of the world population suffers from an autoimmune disease
(Marrack, P. et al, 2001). This underscores the need for inexpensive and effective oral
tolerization therapies. Oral immunization with autoantigens poses several challenges to
effective autoimmune suppression. First, large amounts of autoantigen are generally
required. This constraint may be due to digestive degradation of much of the protein.
Co-delivery of autoantigens with mucosal adjuvants has been shown to boost the
tolerization response to fed autoantigens (Nagler-Anderson, C. et al, 1986; Lider, O. et
al, 1989; Bergerot, I. et al, 1997; Hartmann, B. et al, 1997; Arakawa, T. et al, 1998a;
Arakawa, T. et al, 1999). Another approach to obtain relatively inexpensive
autoantigens for oral tolerance is to have the host generate the protein by injection or
feeding of plasmid DNA encoding the autoantigens (Filippova, M. et al, 2001; Li, A.F.
and Escher, A., 2003; Li, A.F. et al, 2004; Li, A. et al, 2006). Not all individuals may
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respond to the same autoantigen to the same degree. Autoimmune diseases can
frequently be triggered by one or several different autoantigens, and certain antigens may
trigger a lapse in tolerance at various stages throughout disease progression. Examples of
autoimmune diseases propagated by a variety of autoantigens include T1D (pancreatic 13cell autoantigens—glutamic acid decarboxylase, insulin, IA-2, hsp 60, etc.) and systemic
lupus erythematosus (nuclear antigens—dsDNA, histones, ribonucleoproteins, snRNP’s,
etc.) (Bach, J.F. and Chatenoud, L., 2001; Hoffman, R.W., 2001). Prevention or
suppression of these diseases may require co-delivery of several autoantigens given at
precise times during development of the disease. Further, while it is relatively easy to
identify people with autoimmune disease for tolerance/suppression therapy, a
preventative approach will require screening individuals genetically at risk for developing
an autoimmune response. If pathogens prove to be a major cause of autoimmune disease
induction, immunization against these pathogens may be prudent. Finally, several reports
have suggested the possibility for disease induction when oral autoantigens are given
(Genain, C.P. et al., 1996; Bellmann, K. et al., 1998; Blanas, E. and Heath, W.R., 1999).
Accidental ingestion of autoantigens with adjuvants by non-autoimmune individuals
could potentially lead to disease onset, although this possibility has not yet been
confirmed.

Plant-Based Immunotherapies
Plants as Bioreactors for the Synthesis of Edible Vaccines
One of the most promising aspects of using plants for vaccine production and
delivery is owed to their eukaryotic nature. Most plant genomes can accept large gene
inserts without disrupting normal plant functions. Since plant genomes usually contain
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large numbers of multi-copy genes, an insertion into one copy frequently does not affect
the health of the plant. Numerous genes can be introduced into a single plant and several
different transgenic plants can be cross-pollinated to produce multimeric proteins or
multiple antigenic epitopes for broad-spectrum vaccination. Plants also carry out posttranslational modification of newly synthesized proteins, which frequently retains the
biological activity of the foreign protein. The autotrophic nature of plants allows them to
synthesize proteins with medicinal value for the relatively small cost of soil, water, and
harvesting labor.
Plant tissues containing vaccine proteins can be directly consumed with little or
no preparation. During digestion, proteins that elicit an immune response are gradually
released onto the vast surface area of the digestive tract, where antigen uptake occurs.
The combined mucosal surface protected through IgA stimulation is around 400 m —
nearly the size of a basketball court (Goldsby, R.A. et al, 2000). Although oral vaccines
typically require a dosage 100 times higher than that of parenteral injections, the use of
“carrier” peptides as targeting molecules for increased antigen uptake can significantly
reduce this requirement (Czerkinsky, C. et al, 1995; Arakawa, T. et al, 1998b).
The relative safety of plant-based vaccines in comparison to vaccination with
killed or attenuated whole pathogenic viruses/bacteria reduces the need for medically
trained personnel to administer the vaccines. These factors are especially useful in
countries lacking sufficient economic resources and health care facilities. In addition,
transgenic plant seeds can be easily shipped and stored for long periods and do not
require refrigeration. Plant-derived vaccines are free from animal pathogen contaminants
and may not require the use of preservatives. Since the viral and bacterial recombinants
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used to transform plants are not known to invade mammalian cells, further biological
safety is assured. A recent exception was brought to attention when Agrobacterium
tumefaciens was shown to transform mammalian (HeLa) cells (Kunik, T. et al, 2001).
However, the likelihood of genetically modified Agrobacterium escaping the laboratory
environment is unlikely, due to the destruction of the bacteria by antibiotics following
gene delivery to the plant.
Application of conventional agricultural techniques with machinery found in the
local farming community will reduce shipping and production expenses for generating
the vaccine product. Plant species can be selected that are indigenous to the specific
geographical areas where vaccines are needed. However, difficulties remain at the level
of transformation of certain crops. Ultimately, food plants can be selected for
transformation based on hardiness, taste, nutritive value, protein content and availability,
once vaccine effectiveness has been established in model plants easier to transform. The
adaptation of palatable foods for vaccine delivery will help to increase compliance rates,
especially among children. Although plant based vaccines have enormous potential for
protection against disease, little is known about optimum dosage, frequency of
inoculation, or the long-term consequences of consuming plant-generated pathogen
proteins.

Plant Vaccines for Suppression of Autoimmune Disease
T-cells that recognize self-proteins are screened in the thymus, where they are
generally deleted or inactivated (Fry, A.M. et al, 1989). While normal individuals may
possess various autoreactive T-cells with the potential to escalate into autoimmune
disease, peripheral T-cells actively down-regulate these self-recognizing lymphocytes
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(Bach, J.F. and Chatenoud, L., 2001). Autoimmunity occurs when environmental and/or
genetic factors predispose the immune system to recognize the body’s own proteins as
being foreign or threatening (Luppi, P. et al, 1995). This condition alters the balance
between suppressive regulation and lymphocyte activation, shifting the outcome towards
self-destruction. Autoantigens then trigger the immune system to cause tissue-specific or
systemic damage through cytotoxic T-cell mediated destruction and macrophage
stimulated inflammatory responses (Rabinovitch, A. and Suarez-Pinzon, W.L., 1998;
Crane, I.J. and Forrester, J.V., 2005). Autoantigens are taken up by antigen presenting
cells (APCs) such as dendritic cells and macrophages, which “display” the processed
autoantigen for T-cell recognition. Thl lymphocytes with matching receptors to the
presented antigen can recruit other macrophages and cytotoxic T-lymphocytes (CD8+ Tcells) to destroy those cells that produce the autoantigen.
To block autoimmune destruction, self-reactive lymphocytes are suppressed or
eliminated in a process known as immunologic tolerance. Tolerance is defined as “Any
mechanism by which a potentially injurious immune response is prevented, suppressed,
or shifted to a noninjurious class of immune response” (Weiner, H.L., 2000).
Autoantigens given orally have been shown to induce tolerance in animal and human
studies with promising results for several autoimmune diseases, including arthritis,
colitis, multiple sclerosis, myasthenia gravis, thyroiditis, type 1 diabetes, uveitis, and in
tolerization of transplanted tissues (Whitacre, C.C. et al, 1996; Weiner, H.L., 1997;
Arakawa, T. et al, 1999). Since plants express only small amounts of transgenic proteins
(typically 0.01 - 0.4% TSP), they are ideal for oral administration of the low doses of
autoantigen required to induce active suppression.
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In the earliest experiments investigating suppression of multiple sclerosis and
T1D, autoantigen alone was given orally and found to moderately suppress or delay
disease onset (Bitar, D.M. and Whitacre, C.C., 1988; Higgins, P J. and Weiner, H.L.,
1988; Zhang, ZJ. et al., 1991). Large (mg) quantities of autoantigen were usually
required to induce significant oral tolerance, presumably because the protein is partially
degraded in the stomach and is not highly immunogenic. Interestingly, one study
reported that while digestion usually disrupts the metabolic activity of an antigen, oral
tolerance is unaffected and may even be enhanced via association of the GALT with the
remnant protein fragments (Michael, J.G., 1989). To resolve the problem of extracting
large quantities of autoantigens from animals, edible transgenic plants were utilized for
synthesis and delivery of oral autoantigens for suppression of T1D (Ma, S.W. et al,
1997).
Combining autoantigens with adjuvants (immunostimulants) greatly strengthens
the tolerization response, requiring approximately 5,000-fold less autoantigen in one
study (Ploix, C. et al, 1999). Many A-B subunit bacterial toxins have a nontoxic lectin B
subunit that acts not only as an adjuvant, but in addition can bind to specific receptors in
the mucosal-associated lymphoid tissue (MALT), especially of the gut (GALT)
(Czerkinsky, C. et al, 1999a; Falnes, P.O. and Sandvig, K., 2000). The B subunit(s) bind
to sugar-moieties on the surface of gut epithelial cells, stimulating endocytotic uptake of
the A-B holotoxin. Antigen targeting strategies have been developed that take advantage
of the adjuvant/carrier properties inherent in the A and B subunits of bacterial exotoxins.
Although the A subunit is usually a stronger adjuvant than the host-cell-binding B
subunit, it’s toxicity must be eliminated if it is to be used as a vaccines component.
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Cholera toxin (CTX) has been widely used in fusion protein vaccines because of its
highly immunogenic A1 subunit (Sanchez, J. et al., 1997; Lycke, N., 2001) and its
pentamer of B subunits (also immunogenic) that binds to GM1 ganglioside receptors
found on intestinal epithelial cells (Holmgren, J., 1994; Hajishengallis, G. et al, 1995).
CTB fusions with the pancreatic islet autoantigens insulin and glutamic acid
decarboxylase (GAD) have significantly delayed and reduced T1D symptoms following
mucosal delivery in experimental animal models (Bergerot, I. et al, 1997; Arakawa, T. et
al, 1998b; Ploix, C. et al, 1999; Aspord, C. and Thivolet, C., 2002; Sadeghi, H. et al.
2002; Petersen, J.S. et al, 2003; Yuki, Y. et al, 2005; Carter III, J.E. et al, 2006; Li, D.
et al, 2006; Gong, Z. et al, 2007; Ruhlman, T. et al, 2007). At least 100-fold less
insulin and 1,000-fold less GAD were needed to induce immunologic tolerance when
fused to CTB, in comparison with oral administration of unconjugated insulin and GAD
(Arakawa, T. et al, 1998a; Arakawa, T. et al, 1999).
Large quantities of foreign protein can be produced in transformed plants—over
10 kg of protein per acre in some species, which can be synthesized at 1/10 - 1/50 the
cost of production in transgenic mammalian, yeast or bacterial cell cultures (Kusnadi,
A.R. et al, 1997; Arakawa, T. et al, 1998a; Arakawa, T. et al, 1999; Gavilondo, J.V.
and Larrick, J.W., 2000). The majority of this cost is attributed to the process of
purification, which can be eliminated if transformed plant tissues can be consumed
directly.
The first report of an autoantigen being generated by plants was in 1997, when the
T1D pancreatic autoantigen glutamic acid decarboxylase (GAD) was synthesized in
tobacco and potato at a level of 0.4% of the total soluble protein (Ma, S.W. et al, 1997).
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Although GAD expression was low, it was sufficient to suppress the onset of diabetes
when fed to mice genetically destined to develop the disease. Additional studies revealed
that low doses of autoantigens are better at inducing tolerance through the immunological
mechanism of active suppression, whereas high autoantigen doses can incur immune
“paralysis” (anergy) with little or no active suppression (Friedman, A. et al., 1994). To
make autoantigens more immunogenic, gene fusions were made with the diabetic
autoantigen insulin and the non-toxic B subunit of cholera toxin (CTB). CTB was shown
to be a strong mucosal adjuvant and carrier molecule when co-delivered or chemically
fused with antigens (Czerkinsky, C. et al, 1996). Chemically conjugated insulin-CTB
fusion proteins were shown to be effective in diabetes suppression when fed to non-obese
diabetic (NOD) mice using as little as one dose containing 500 - 5,000 times less
autoantigen than unconjugated insulin given orally (Bergerot, I. et al, 1997). Edible
plants were used to generate diabetes autoantigens genetically fused to CTB. The plantsynthesized insulin-CTB and GAD-CTB fusion proteins were found to be more effective
in the reduction of diabetes symptoms than were insulin or GAD alone when fed to NOD
mice (100-fold and 1,000 fold less required, respectively) (Arakawa, T. et al, 1998a;
Arakawa, T. et al, 1999).
Additional methods for improvement of oral tolerance immunotherapy include the
use of alternative enterocyte-binding proteins (Carter III, J.E. et al, 2006). Another
immunotolerization approach is to introduce genes encoding more than one autoantigen
into a plant. Eating these will provide exposure to a broader spectrum of tolerizing
autoantigens, which may be especially useful for the suppression of autoimmune diseases
in which several self-proteins act as autoantigens. A proactive strategy to enhance
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autoimmune disease prevention could be to supply the population with mucosal vaccines
that protect against pathogens suspected of eliciting self-reactive antibodies. This
approach would require widely available and inexpensive subunit vaccines. Plant
vaccines would be ideal for mass immunization programs. Immunogenic epitopes would
be selected that provide protective immunity against the offending viruses or bacterial
pathogens, but that were not cross-reactive with antibodies to self-proteins. However,
prophylactic vaccination in humans may have to wait until more is known about the
mechanisms of autoimmune disease immunopathogenesis and the safety of these plantbased mucosal vaccines is determined.

Ricin Toxin B Chain as a Delivery and Adjuvant Protein
Ricin toxin B chain (RTB) was selected among A-B exotoxins for immunoenhancement of autoantigens because it offers several unique advantages over the
bacterial toxin B chains. Ricin is a plant protein normally produced in castor bean
(Ricinus communis) and is therefore more likely to be synthesized in its native
conformation in transgenic plants. The RTB chain has a more extensive variety of
cellular receptors to dock onto than other toxin B chain lectins such as those of cholera
toxin (CTB), heat-labile enterotoxin from E. coli (LTB), and shiga toxin (STB). There
are approximately 3xl07 RTB binding sites on a single HeLa cell (Sandvig, K. and van
Deurs, B., 1994). RTB gains access to the intracellular environment through binding of
cell glycoproteins or glycolipids with terminal galactose residues and then taken up by
both clathrin-dependent and independent pathways (Sandvig, K. and van Deurs, B.,
1994). RTB is folded as a monomer and seems capable of carrying large fusion proteins
without interference of receptor binding. Molecules as large as the 27 kDa green-
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fluorescence protein (GFP) have been conjugated to RTB and expressed in transgenic
tobacco (Medina-Bolivar, F. et al., 2003). The GFP-RTB fusion protein retained the
ability to bind galactose and was immunogenic in mice. Other RTB fusion proteins have
been generated in our lab for the purpose of creating edible vaccines that protect against
rotavirus (Choi, N.W. et al, 2006b, 2006c, 2006a).
The B chains of most pentameric bacterial exotoxins require full assembly to bind
to receptor complexes. Because large fusion proteins may inhibit the pentamer formation
through steric hinderances, this is a potential downfall of using A-B5 toxins such as CTB,
LTB, and STB. This assembly interference was encountered when a 55 kDa GAD
protein that was linked to CTB had failed to produce pentamers (Carter III, J.E. et al.
2006). Despite not functioning as a delivery molecule, the CTB-GAD55 monomers still
generated a significant immunotolerance response when fed to NOD mice as compared to
untreated animals. This suggests that the adjuvant properties of CTB are still relevant
even without lectin activity.
Because RTB has an N-terminal segment that protrudes away from the main
dumbbell-shaped portion of the B chain, the autoantigen human proinsulin (INS) was
genetically linked at this end of RTB to avoid problems with protein assembly. A
computer-predicted model of the INS-RTB fusion protein is shown in Figure 2. The
INS-RTB fusion protein was concurrently fed to NOD mice during the CTB-GAD trial
and demonstrated comparable levels of autoimmune suppression. Because the INS-RTB
protein was synthesized in E. coli, most (>92%) of the fusion protein was misfolded and
was recalcitrant to renaturation. Therefore, genes encoding the INS-RTB protein were
introduced into potato plants by Agrobacterium-mQd\?iiQ& transformation to synthesize
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natively-folded, properly glycosylated INS-RTB fusion protein with carrier and adjuvant
characteristics (Chapter 3).
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Figure 1: Worldwide Incidence of Type 1 Diabetes in Children <14 Years of Age.
Values are age-adjusted and listed in descending order of incidence (per 100,000 people
per year). Note that many of the countries with the highest incidence of disease are
located north or south of the equatorial belt, where sunshine is less intense annually and
therefore dermal vitamin D synthesis is lower, on average. Other countries with a high
incidence of people with T1D are industrialized nations, where children and adults spend
more time indoors and out of the sun. Despite being in a sunny location, Kuwait—the
country with the 4th highest incidence of T1D—might have increased numbers of people
with autoimmune diabetes due to their darker skin color and a tendency to clad
themselves extensively in clothes that can block vitamin D synthesis.
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Figure 2: Computer-Predicted Model of P-INS-RTB Fusion Protein.
Human proinsulin (INS) was genetically linked to the N-terminal extended portion of the
ricin toxin B chain (RTB) to avoid potential folding problems that might occur with a Cterminal fusion. The C-termini of RTB is buried within the protein globule (not shown).
In the plant vector (see Chapter 3) a p-phaseolin (P) sequence was also included upstream
to the INS gene to direct protein synthesis in the endoplasmic reticulum (ER). The P
sequence results in the build-up of P-INS-RTB inside the ER and helps to avoid
cytoplasmic degradation of the transgenic protein.
Structure prediction utility:
Geno3D—Automatic comparative molecular modelling of protein. Combet C., Jambon, M., Deleage, G.
and Geourjon, C. (2002). Bioinformatics. 18:213-214. http://geno3d-pbil.ibcp.fr
3D modeling software:
QuteMol. http://qutemol.sourceforge.net/

41

Lumen

Dendritic Ceil
Pathway

M Cell
Pathway

Enterocyte
Pathway

Virus
Pathway

<s>

Gut
Epithelium
Lamina
Propria
Nuile

J P- Cell
Apoptosis
(T1D) r

CTL

h2o2
NO
ifn-yV
B
TNF-a/p
Ab (autoreactivej

m^

cell

r

^

INF-a
IFN-y
IL-17
IL-22

Th17
RORyt

42

Gata-3

Figure 3: Adjuvant-Autoantigen Suppression of Type 1 Diabetes.
In this model, immature dendritic cells (iDC) in the gut periphery take up INS-RTB
fusion protein from the intestinal lumen. Alternatively, microfold (M)-cells overlaying
the Peyer’s patches take up INS-RTB by endocytosis, where it is then delivered to
antigen presenting cells, particularly dendritic cells and macrophages that reside in the
lamina propria. Autoantigens, made more immunoreactive by adjuvant (RTB) linkage,
alter iDC processing or maturation that favors DC secretion of IL-10 (or suppression of
IL-12 secretion). The anti-inflammatory cytokine IL-10 directs cognate ThO cell
development into immunosuppressive Th2 or iTreg (Th3 or Trl) cell phenotypes. INSRTB may also activate CD4+CD25+ native regulatory T cell (nTreg) synthesis of
transcriptional activator protein FOXP3, leading to further immune suppression activity.
Figure adapted from:
Afzali B. et al. (2007), Iwasaki A. and Kelsall, B.L. (2000), and a 2008 NIH R01 application submitted by
W. Langridge and I. Fodor to the National Institute of Digestive and Diseases of the Kidney (NIDDK)
entitled, Immunostimulation of Autoantigen Mediated Tolerance.
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Table 1: Diabetes Health Statistics (U.S.A.)
Heart disease
and stroke

Heart disease and stroke account for -65% of deaths in people with diabetes.
Adults with diabetes have heart disease and stroke death rates about 2-4 times
higher than adults without diabetes.

High Blood
Pressure

About 75% of adults with diabetes have blood pressure greater than or equal to
130/80 mm Hg or use prescription medications for hypertension.

Blindness

Leading cause of new cases of blindness among adults aged 20 - 74 years.
Diabetic retinopathy causes 12,000 - 24,000 new cases of blindness each year.

Kidney
Disease

Leading cause of kidney failure, accounting for 44% of new cases in 2005.
In 2005, 46,739 people with diabetes began treatment for end-stage kidney disease
in the United States and Puerto Rico while 178,689 people had end-stage kidney
disease that required chronic dialysis or a kidney transplant.

Nervous
System Disease

About 60 - 70% of people with diabetes have mild to severe forms of nervous
system damage. The results of such damage include impaired sensation or pain in
the feet or hands, slowed digestion of food in the stomach, carpal tunnel syndrome,
erectile dysfunction, or other nerve problems.
Almost 30% of people with diabetes ages 40 years or older have impaired
sensation in the feet—for example, at least one area that lacks feeling.
Severe forms of diabetic nerve disease are a major contributing cause of lowerextremity amputations.

Amputations

More than 60% of nontraumatic lower-limb amputations occur among people with
diabetes.
In 2004, about 71,000 nontraumatic lower-limb amputations were performed in
people with diabetes.

Dental Disease

Periodontal, or gum, disease is more common in people with diabetes. Among
young adults, those with diabetes have about twice the risk of those without
diabetes.
People with poorly controlled diabetes—A1C greater than 9 percent—were nearly
three times more likely to have severe periodontitis than those without diabetes.
Almost one-third of people with diabetes have severe periodontal disease with loss
of attachment of the gums to the teeth measuring 5 millimeters or more.

Complications
of Pregnancy

Poorly controlled diabetes before conception and during the first trimester of
pregnancy among women with T1D can cause major birth defects in 5 to 10
percent of pregnancies and spontaneous abortions in 15 to 20 percent of
pregnancies.
Poorly controlled diabetes during the second and third trimesters of pregnancy can
result in excessively large babies, posing a risk to both mother and child.

Other
Complications

Uncontrolled diabetes often leads to biochemical imbalances that can cause acute
life-threatening events, such as diabetic ketoacidosis and hyperosmolar, or
nonketotic, coma.
People with diabetes are more susceptible to many other illnesses and, once they
acquire these illnesses, often have worse prognoses. For example, they are more
likely to die with pneumonia or influenza than people who do not have diabetes.
People with diabetes ages 60 years or older are two to three times more likely to
report an inability to walk a quarter of a mile, climb stairs, do housework, or use a
mobility aid compared with people without diabetes in the same age group.

Source: http://diabetes.niddk.nih.gov/DM/PUBS/statistics/
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Table 2: Characteristics of Regulatory T-Cell Subsets
Cell Type

Regulatory
Mechanism

CD4+CD25+
(nTregs)

Cell contact
dependent; cytokines
(IL-10?)

CD4+CD25"
(nTregs)
Trl iTregs
Th3 iTregs

Mostly cytokine
mediated
Mediated by IL-10
Mediated by TGF-|3

NKTregs

IL-4, IL-10, TGF-|3,
cytotoxicity

Cell contact
dependent;
CD8+ Tregs
cytotoxicity;
cytokines
CD8+CD25" Induction of
ILT3/ILT4 on DCs
Tregs
Cell contact?
y8 T-cells
Cytokines?
nTregs: Natural T-regulatory cells
iTregs: Inducible T-regulatory cells
ILT: Immunoglobulin-like transcript
DCs: Dendritic cells
APCs: Antigen presenting cells

Foxp3
Expression

Yes

Target
Cells

Functions

T-cells,
APCs

Suppression of autoimmunity;
inhibition of allograft rejection and
of immune responses induced by
microbial infection; mediation of
UV-induced immunosuppression

T/B-cells,
APCs
T-cells
T-cells

Probably
Yes
?

?

T-cells,
APCs,
tumor cells

Yes

T-cells

Probably

DCs/APCs

?

?

Suppression of autoimmunity
Suppression of autoimmunity
Suppression of autoimmunity
Suppression of autoimmunity;
Elimination of tumors and
pathogens; mediation of UVinduced suppression of protective
tumor immunity
Suppression of autoimmunity;
regulation of peripheral TCR
repertoire
Regulation of autoimmunity
Generation of peripheral tolerance

(Adaptedfrom Beissert, S. et al., 2006; Pyzik, M. and Piccirillo, C.A., 2006; Bopp, T. et
al., 2007)
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Abstract
Several bacterial and plant enterotoxin B subunit-islet autoantigen fusion proteins
were compared for their ability to serve as islet autoantigen carriers and adjuvants for
reduction of pancreatic islet inflammation associated with Type 1 diabetes. The cholera
toxin B subunit (CTB), the heat-labile toxin B subunit from enterotoxigenic E. coli
(LTB), the Shigella toxin B subunit (STB) and the plant toxin ricin B subunit (RTB) were
genetically linked to the islet autoantigens proinsulin (INS) and glutamic acid
decarboxylase (GAD). The adjuvant-autoantigen gene fusions were transferred to a
bacterial expression vector and the corresponding fusion proteins synthesized in E. coli.
The purified adjuvant-autoantigen proteins were fed to five-week-old non-obese diabetic
(NOD) mice once a week for four weeks. Histological examination of pancreatic islets
isolated from inoculated mice showed significant levels of insulitis reduction in
comparison with uninoculated mice. The ratio of serum anti-INS and anti-GAD IgG2c to
IgGl antibody isotype titers increased in all ligand-autoantigen inoculated animal groups,
suggesting an increase in effector Th2 lymphocytes in B subunit-mediated insulitis
suppression. The results of these experiments indicate that bacterial and plant
enterotoxin B subunit ligand-autoantigens enhance insulitis reduction in NOD mice. This
research prompts further exploration of a multi-adjuvant/autoantigen co-delivery strategy
that may facilitate Type 1 diabetes prevention and suppression in animals and humans.

Key Words: oral tolerance, autoimmune, Type 1 Diabetes, adjuvant, cholera, heat-labile
enterotoxin, shigatoxin, ricin.
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Introduction
Type 1 diabetes is a Thl lymphocyte-mediated autoimmune disease resulting in
destruction of insulin-secreting |3-cells of the pancreas by inflammatory responses
associated with cytotoxic lymphocyte infiltration of pancreatic islets—insulitis
(Eisenbarth, G.S., 1986; Tisch, R. and McDevitt, H., 1996). Partial suppression of
diabetes symptoms can be established by oral delivery of small amounts of islet
autoantigens, such as insulin and glutamic acid decarboxylase—GAD (Zhang, Z.J. et al,
1991; Weiner, H.L. et al, 1994; Czerkinsky, C. et al, 1999a). Previous experiments
have shown that suppression of insulitis and hyperglycemia in diabetic animals can be
substantially enhanced if islet autoantigens are linked to the lectin B subunits of the
pentameric cholera toxin—CTB (Bergerot, I. et al, 1997; Arakawa, T. et al, 1998b;
Arakawa, T. et al, 1999). While pentameric delivery systems may possess advantages
for antigen delivery, certain limitations for adjuvant function may exist that include: 1.)
Assembly of monomeric subunits of CTB into pentameric oligomers, considered
essential for membrane receptor binding. 2.) Pentameric toxin molecules require
recruitment of five receptor molecules in the cell membrane prior to toxin uptake into the
cell. 3.) Cholera toxin and other pentameric toxins require specific ganglioside receptor
molecules (such as Gmi) that may not be abundantly available on all mucosal epithelial
cells, 4.) The molecular mass of fused antigens can impose steric limitations on the
kinetics of pentamer assembly. The non-toxic B subunits from other AB-toxins may
compliment these limitations by binding to alternate membrane receptor molecules. An
alternative to using B subunits which require pentamer assembly is to fuse autoantigens
to toxins with only one B subunit. This may facilitate the transport of larger sized
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antigens across the enterocyte membrane for presentation to gut-associated lymphoid
tissues (GALT).
AB enterotoxins from other microbial pathogens and plants may possess
autoantigen delivery and adjuvant functions similar to or superior than CTB for
complementation or replacement of CTB-autoantigen mediated diabetes suppression. To
examine the adjuvant effects of other enterotoxins, genes encoding the B subunit of E.
coli heat labile enterotoxin (LTB), the Shigella enterotoxin (STB) and the plant
enterotoxin ricin (RTB) from Ricinus communis were genetically linked to the pancreatic
islet |3-cell molecules proinsulin (INS) and GAD in an E. coli expression vector.
Following biosynthesis, isolation, and refolding of the toxin B subunit-autoantigen fusion
proteins from E. coli, the conjugated proteins were fed to juvenile non-obese diabetic
(NOD) mice. In this study, we demonstrate that pancreatic tissues isolated from ligandautoantigen inoculated mice show reduced levels of islet infiltration by lymphocytes
when compared to mice inoculated with phosphate-buffered saline (PBS) or the CTB
ligand alone. Further, we show that the ratio of IgGl and IgG2c antibody isotypes
quantified in the sera of fusion protein fed mice suggest generation of a Th2 lymphocytemediated immuno-suppressive response. Together, the data supports the notion that
enhanced autoantigen suppression of pancreatic islet inflammation can be generated by
linking a variety of monomeric or pentameric enterotoxin B subunits to islet p-cell
autoantigens.
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Materials and Methods
Expression and Purification of Enterotoxin B Subunit-Autoantigen
Fusion Proteins in E. coli
Gene fusion constructs used in this study are presented in Figure 4. A cDNA
fragment encoding a 5 kDa peptide (aa 509-543) located proximal to the C-terminus of
human GADes (designated GAD5), was genetically linked to the C-terminus of individual
cDNA fragments encoding CTB, LTB, and STB. In addition, a cDNA fragment
encoding aa 89-585 of human GADes was linked to the C-terminus of the CTB gene.
The 55 kDa truncated form of human GADes, which lacks the N-terminal segment that
normally anchors GAD to cell membranes, was designated GAD55. A gene encoding
human proinsulin, perhaps the major diabetes autoantigen, was linked to the N-terminus
of RTB, which is located away from the ligand’s receptor binding clefts. The toxin B
subunit-autoantigen fusion genes were cloned into E. coli expression vector pRSET(A)
(Invitrogen™, Carlsbad, CA) and assessed by DNA sequence analysis to confirm the in
frame linkage of the toxin B subunit ligand and autoantigen DNA fragments.
Recombinant vectors were then introduced into the E. coli strain BL21(DE3)pLysS
(Invitrogen™, Carlsbad, CA) by electroporation for production of the toxin B subunit
fusion proteins. Recombinant fusion proteins expressed in E. coli were purified by
isolating the 6xHis-tagged proteins from lysed cells using metal chelation
chromatography. Briefly, a bacterial colony harboring each recombinant plasmid was
inoculated into 25 ml of LB medium and incubated overnight with shaking at 37°C. The
culture was transferred to 250 ml LB medium and cultured to an optical density of 0.4 0.6 (ODeoo)- Fusion protein biosynthesis was induced by adding the lac gene inducer
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isopropyl-|3-D-thiogalactopyranoside (IPTG) to the cultures at a 1 mM final
concentration, followed by incubation at 37°C for an additional 3 - 6 h. The bacteria
were pelleted by centrifugation at 3,000 RPM for 15 min. Cells were lysed by a freezethaw cycle, followed by sonication. Inclusion bodies were dissociated in buffer “Z” (8 M
urea, 100 mM NaCl, 20 mM HEPES, pH 8.0). Cell wall debris was removed by
centrifugation at 14,000 RPM, 4°C. The clarified bacterial lysate supernatant was loaded
onto a column packed with Ni2+-NTA (Invitrogen’s ProBond™resin). The column was
washed with 50 ml of Buffer Z plus 10 mM imidazole to remove unbound bacterial
proteins. The hexahistidine tagged ligand-autoantigen fusion protein was eluted from the
column with buffer Z containing 250-500 mM imidazole. Recombinant protein yield
was measured by the Bradford protein assay method (Bio-Rad, Hercules, CA).

Immunoblot Identification of Toxin B Subunit-Autoantigen
Fusion Proteins
Approximately 5.0 pg of each purified refolded recombinant protein was directly
loaded onto a 10% sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) and
separated by electrophoresis at 120 V for 1 h. The separated protein bands were
transferred from the gel to a nitrocellulose membrane (MSI Inc.) by electroblotting on a
semi-dry blotter for 2 h at 30 V and 75 mA. The membrane was incubated overnight at
4°C with anti-GAD primary antibody (Sigma®, St. Louis, MO) at a 1:3,000 dilution, or
with anti-His antibody (Sigma) at a 1:1,000 dilution. Following incubation, the
membrane was washed 3 times with TEST buffer (20 mM Tris, pH 7.5, 500 mM NaCl,
0.05% Tween-20) and incubated with secondary antibody, anti-rabbit IgG alkaline
phosphatase conjugate (Sigma), at a 1:10,000 dilution for 1 h at room temperature.
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Finally, the membrane was washed 3x in TEST and incubated with the chromogenic
substrate BCIP/NPT (Sigma) in the dark for 10 min at room temperature. The color
reaction was stopped at optimal staining by washing the membrane 3x in distilled water.
The protein bands were photographed on a light box.

Analysis of Enterotoxin B Subunit-Autoantigen
Fusion Protein Folding
The receptor binding ability of each lectin-autoantigen fusion protein was
measured by enzyme-linked immunosorbent assay (ELISA). Flat-bottom 96-well
microtiter plates were coated with lectin-specific receptors as follows:

RTB Substrate Binding Assay
To each microtiter plate well, 100 ^il of asialofetuin (Sigma) dissolved in 50 mM
bicarbonate buffer (pH = 9.6) was added at a concentration of 10 pg/ml (1.0 pg/well).
The asialofetuin was bound to the plate O/N at 4°C. The plate was washed three times, 5
min each with 300 pl/well of phosphate buffered saline (PBS) containing 0.05%
polyoxyethylenesorbitan monolaurate (Tween 20) with mild shaking. To block non
specific binding, a 1% solution of bovine serum albumin (BSA) in PBS was added (300
pl/well) and the plate incubated for 2 h at 37°C. The wells were washed 3x with PBS +
Tween 20 (PBST). E. co/z-purified INS-RTB diluted in PBS was added to each well (100
pl/well) at selected concentrations (previously determined by Bradford assay) and the
mixture was incubated O/N at 4°C. Wells containing either PBS or INS were used as
negative controls. After washing the wells 3x with PBST, 100 pi of a 1:1,000 dilution of
rabbit anti-ricin antibody (Sigma) in PBS + 0.5% BSA was added to each well and the
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mixture incubated 0/N at 4°C. The wells were washed as previously described and
incubated 2 h with 100 pi mouse anti-rabbit IgG conjugated to alkaline phosphatase
(Sigma) diluted 1:10,000 with PBS containing 0.5% BSA. After 3x washing with PBST,
100 pi of the chemiluminescent substrate Lumi-Phos® Plus (Lumigen Inc., Southfield,
MI) was added to each well and the mixture incubated for 30 min at 37°C, followed by 5
min equilibration at room temperature. Light emission was detected in a Dynatech
ML3000 Microtiter Plate Luminometer (Dynatech Laboratories). All samples were
measured in triplicate.

CTB/LTB Binding Assay
Microtiter plate wells were coated with 100 pi of a 3.0 pg/ml solution of
monosialoganglioside Gmi (Sigma) diluted in 50 mM bicarbonate buffer (pH = 9.6) O/N
at 4°C. Washing, blocking, lectin binding, and substrate activation steps were performed
as described in the RTB binding assay protocol. After PBST washing, mouse anti
cholera toxin (Sigma) was added as the primary Ab, followed by incubation with
alkaline-phosphatase conjugated secondary Ab. Detection of substrate
chemiluminescence was performed as previously described for the RTB binding assay.

STB Binding Assay
Microtiter plate wells were coated with 100 pi of a 2.0 pg/ml solution of
globotriaosylceramide (Gb3) receptor molecules (Matreya Inc., Pleasant Gap, PA)
solubilized by dilution in chloroform:methanol:water (65:25:4 vol/vol). The solvents
were removed by evaporation from the wells in a sterile laminar flow hood for ~2 h at
room temperature. The wells were washed 3x with PBS and blocked with 300 pl/well of
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PBS + 1% BSA for 2 h at room temperature. After an additional 3x washing with PBS,
the wells were washed once with 25 mM Tris buffer (pH 8.3). The STB-GAD5 fusion
protein was serially diluted with 25 mM Tris buffer (pH 8.3) and added to each well (100
jil/well). The wells were washed in triplicate with PBS, followed by addition of mouse
anti-shiga toxin-1 B subunit antibodies (Toxin Technology Inc., Sarasota, FL) diluted to
10 p,g/ml with PBS + 0.5% BSA. Subsequent washing, secondary antibody incubation,
and substrate activation steps were the same as described for the RTB binding assay.

Active Suppression of Type 1 Diabetes
Four-week old female NOD mice were purchased from Taconic Farms
(Germantown, NY) and maintained in the Loma Linda University animal care facility.
Induction of oral tolerance was based on a total of 11 experimental immunization groups
as shown in Table 3 (n = 8 mice/group). At five weeks of age, each mouse was gavaged
once per week for a total of 4 weeks with 50 pg of purified recombinant toxin B subunitautoantigen fusion protein dissolved in 0.3 ml of 350 mM sodium bicarbonate buffer (pH
= 9.0). At 10 weeks of age, the mice were sacrificed by CO2 anoxia. Pancreatic tissue
and blood samples were collected immediately following euthanasia. The mice in
experimental Group 10 were gavaged with an equal amount of insulin (Sigma).

Histopathological Analysis of Pancreatic Islets
Pancreatic insulitis levels were measured based on the extent of lymphocyte
infiltration into the islets of Langerhans (see Figure 7). Pancreatic tissues from
immunized mice were fixed with formalin, stained with hematoxylin, and counterstained
with eosin. Insulitis progression was scored by two individuals (double blind), on a 5-
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level scale increasing from 0-4, where level 4 indicates the maximum amount of
insulitis. A score of 0 was considered to be normal islets with no indication of
lymphocyte infiltration. A of score 1 indicated peri-islet infiltration with lymphocytes
occupying less than 20% of the islet surface. A score of 2 indicated peri/intra-islet
lymphocyte infiltration with lymphocytes occupying 20%-40% of the islet surface. A
score of 3 indicated intra-islet infiltration with lymphocytes penetrating and occupying
40%-70% of the islet. A score of 4 indicated massive intra-islet lymphocyte infiltration
involving lymphocyte occupation of more than 70% of the islet.

Detection of Anti-GAD and Anti-Insulin Antibodies
To eliminate variability in luminescence readings among mice in each
experimental group, serum was pooled from all the animals in each immunization group
and assayed by chemiluminescent ELISA methods for the presence of anti-GAD
antibody isotypes IgGl and IgG2c in those experimental groups gavaged with GAD or
GAD fusion proteins. Alternatively, experimental groups gavaged with insulin or INSRTB fusion proteins were assayed with anti-insulin primary antibodies (Arakawa, T. et
al., 1997). Briefly, the wells of a flat bottom 96 well microplate were coated with 500
rcg/well of human insulin or human GADes (Sigma Chem. Co., St Louis, MO). The
pooled sera (1:50 dilution) were added to the antigen-coated microplate. After washing
3x with PBST, the bound antibodies were reacted with alkaline phosphatase-conjugated
goat anti-mouse IgGl and anti-mouse IgG2c antibodies. The chemiluminescent reaction
was initiated by adding the alkaline phosphatase substrate Lumi-Phos Plus™ (Lumingen,
MI) at 0.2 ml/well. After 10 min. r.t. incubation, the relative light units (RLU) were
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measured in comparison to wells incubated without antigen in a ML 3000 Microtiter
Plate Luminometer (Dynatech Laboratories, CA).

Statistical Analysis
Statistical analyses of mouse experimental groups were performed using a one
way analysis of variance method (ANOVA). Insulitis scores were presented as the mean
± 95% confidence interval. A probability value of/? < 0.05 was considered statistically
significant.

Results
Toxin B Subunit Autoantigen Fusion Protein Expression in E. coli
E. co/z-synthesized GAD5 peptide and toxin B subunit-GAD fusion proteins were
identified on immunoblots with a monoclonal antibody made against the C-terminal
epitope of human GADes (aa 514-530) (Figure 5A). The CTB-GAD5 fusion protein was
detected in both monomeric (~22 kDa) and multimeric forms (note that depending on the
cloning site, the pRSET(A) vector can add as much as 9 kDa to the expressed protein).
The LTB-GAD5 fusion protein generated a banding pattern similar to CTB-GAD5, which
was anticipated since the two pentamers share ~80% amino acid homology. The LTBGAD5 fusion protein formed multimers (largely dimers), but to a lesser extent in
comparison with the CTB-GAD5 fusion protein. The STB-GAD5 fusion protein was
detected at a lower molecular weight than CTB-GAD5 and LTB-GAD5 due to the smaller
size of the STB subunit (7.7 kDa). The CTB-GAD55 fusion protein generated a single
band of ~72 kDa, which approximated the combined size of CTB and GAD55. Steric

56

hindrance generated by the large size of GAD55 may have restricted CTB-GAD55 fusion
protein folding to only the monomeric form (Figure 5A, lane 5; Figure 5B, lane 3).
The molecular structure of the E. co/z-produced toxin B subunit-autoantigen
fusion proteins was confirmed by immunoblot analysis using anti-histidine Ah (B). The
GAD5 and ligand-autoantigen fusion proteins CTB-GAD55, CTB-GAD5, LTB-GAD5, and
STB-GAD5 had approximately the same molecular wt. as in Figure 5 A, where anti-GAD
Abs were used. Bacterial-expressed CTB generated both monomeric and pentameric
bands. Monoclonal anti-Flis antibodies used in Figure 5B were less reactive than the
polyclonal anti-GAD antibodies used in Figure 5A, thus pentamer formation was more
difficult to detect after immunoblot staining. The INS-RTB fusion protein was detected
as a single band at 46 kDa.

Lectin Binding Detection by Chemiluminescent ELISA
The renatured fusion proteins showed a concentration-dependent increase in
receptor binding capacity (Figure 6), which indicates that the functional portion of the
toxin B subunits were properly folded and possessed the capacity to bind enterocyte
receptors. CTB-GAD55 was the only fusion protein that had poor binding activity (data
not shown). This was likely due to the large GAD55 molecule interference with CTB
pentamer formation. Hence, only CTB-GAD55 monomers were detected by immunoblot
(Figure 5A, lane 5) methods.

Insulitis Suppression
To examine the effects of orally administered toxin B subunit-autoantigen fusion
protein effects on insulitis reduction in juvenile prediabetic mice, female NOD mice were
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fed 50 jig of each fusion protein, once per week for 4 weeks starting at 5 weeks of age.
The mice were sacrificed at 10 weeks of age for histopathological analysis of pancreatic
islet tissues. The mean insulitis scores for each group comparison is shown in Figure 8.
The cumulative data for all groups is listed from highest to lowest mean insulitis score in
Table 4. To determine whether assembly of CTB-GAD5 monomer into cholera toxin-like
pentamers was essential for CTB adjuvanticity, we immunized mice with an identical
amount of boiled (denatured) CTB-GAD5. This result suggests that assembly of CTBGAD5 fusions into pentamers capable of binding to Gmi ganglioside possesses an
additional carrier (adjuvant) function e.g., autoantigen delivery to the mucosal immune
system. To determine whether bacterial proteins and LPS exert independent effects on
immune suppression, we examined islets from mice gavaged with a clarified homogenate
of CTB-GAD5 protein-producing E. coli cells containing approximately the same amount
of CTB-GAD5 used for inoculation of the other animal groups. The effect of pentameric
toxin B subunits on insulitis reduction was evaluated by oral inoculation of NOD mice
with CTB-GAD5, LTB-GAD5, and STB-GAD5 fusion proteins in comparison with GAD5
alone. In comparison with the PBS fed experimental control group, all ligandautoantigen fusion proteins and GAD5 alone generated a significant reduction in insulitis
(Figure 8). The average insulitis score for all B subunit-GADs fusion proteins was lower
than the insulitis score of GAD5 alone indicating linkage to the B-toxin lectin generated
an adjuvant effect. Although not statistically significant, CTB-GAD5 generated the
lowest mean insulitis score of all B subunit ligand-GADs fusion proteins measured.
The ability of RTB to suppress insulitis was examined by gavaging 5-week-old
NOD mice with INS-RTB fusion protein in comparison with an experimental group fed
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an equal amount of insulin. The insulitis score of the INS-RTB inoculated group (0.9 ±
0.19), was significantly lower than that found in mice gavaged with insulin alone (1.9 ±
0.25) or PBS (3.53 ± 0.24) (Figure 8E). The percentage of total intact islets in INS-RTB
inoculated mice was similar to that found for diabetes suppression with CTB-GAD5
(Table 5). All therapies showed a significant reduction in insulitis compared to untreated
animals (p ^ 0.05).

Immune Response in NOD Mice
One week after the final ligand-autoantigen inoculation, humoral immune
responses against GAD and INS were examined. In comparison to the amount of IgG2c
isotype, there was a significant increase in the IgGl antibody titer against GAD in sera of
mice gavaged with GAD5, CTB-GAD5, CTB-GAD55, LTB-GAD5, and STB-GAD5
(Figure 9). While anti-GAD IgG2c isotype antibody levels remained mostly unchanged,
mice gavaged with the clarified E. coli cell lysate extracts containing CTB-GAD5 fusion
protein showed a dramatic increase in IgGl antibody isotype titers to GAD in comparison
with mice fed nickel column purified CTB-GAD5 fusion protein (Figure 9A). The titers
of anti-insulin IgGl antibodies in the sera of mice gavaged with either insulin, or INSRTB fusion protein increased in comparison with IgGl titers in NOD mice fed PBS. The
experimental results suggest that oral inoculation of prediabetic NOD mice with GAD5 or
INS autoantigens and the AB toxin B subunit-autoantigen fusion proteins induce a Th2
immune response dependent on the immunogenic nature of the antigen fused to the
ligand. Further, linkage with each of the AB toxin ligands used in this study consistently
enhances the suppression of insulitis.
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Discussion
Prevention of autoimmune diabetes by oral autoantigen treatment has been
demonstrated in a number of animal autoimmune diabetes models (Czerkinsky, C. et al.
1999b). Further, the effectiveness of autoantigen conjugation with CTB for increased
suppression of Type 1 diabetes insulitis and for reducing effective autoantigen dosage has
been amply demonstrated in these systems (Holmgren, J. et al, 1993; Sun, J.B. et al.
1994; Sadeghi, H. et al, 2002; Bregenholt, S. et al, 2003). Enhanced antigen
presentation to the mucosal immune system following conjugation of the antigen to CTB
was demonstrated to be dependent on CTB-antigen complex binding to Gmi receptors on
the enterocyte apical membrane surface, especially M-cells and ultimately on the surface
of antigen presenting cells (Dertzbaugh, M.T. et al, 1990). The resultant T-cell
responses were demonstrated to be antigen specific. These earlier studies indicated
favorable immune modulating effects of CTB subunit-receptor interactions, which
established the basis for exploration of immune modulation provided by a variety of
microbial and plant toxin B subunits with differing receptor specificities and adjuvant
properties. These differences in receptor binding properties may permit complementation,
replacement, or even synergy with CTB in carrier/adjuvant-based mucosal vaccine
systems for immune suppression of Type 1 diabetes and other Thl lymphocyte-mediated
autoimmune diseases (Keusch, G.T. et al, 1991; Rutenber, E. and Robertus, J.D., 1991;
Fraser, M.E. et al, 1994; Haicheur, N. et al, 2000; Medina-Bolivar, F. et al, 2003).
We have described construction of pentameric B subunit adjuvants (CTB, LTB,
and STB) linked to the pancreatic autoantigen GAD55, a truncated version of GADes that
lacks the 10 kDa membrane-binding section. In addition, we have linked to CTB the
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short GAD5 (5 kDa) C-terminal peptide that contains a number of epitopes implicated in
autoimmune diabetes (Kaufman, D.L. et al., 1993; Patel, S.D. et al., 1997; Tisch, R. et
al, 1999; Tisch, R. et al, 2001). Oral delivery of immunogenic epitopes close to the
GAD C-terminus were shown to prevent diabetes symptoms in a manner similar to that
found in full length GADes protein (Tisch, R. et al, 1999). The success of CTB
pentamer assembly necessary for receptor binding was found to be dependent on the size
of the linked antigen protein, and restrictions are most likely due to steric hindrance
caused by the larger antigens. Based on this observation, GAD5 was selected to provide a
reduction in antigen size without dramatically compromising pentameric assembly and
related autoantigen toleragenicity.
In addition to using toxin B subunit pentamers as adjuvants, a recently
constructed fusion between the monomeric plant toxin B chain (RTB) and insulin was
included to assess the efficacy of monomeric toxin B subunits for their effectiveness in
suppressing insulitis. Since RTB is monomeric, steric hindrance by larger fusion proteins
was not expected to be problematic during protein folding. Insulin was chosen as a
candidate tolerogen because it is now believed to be the primary autoantigen in the
initiation of Type 1 diabetes (Kent, S.C. et al, 2005; Nakayama, M. et al, 2005). In the
future, a combinatorial therapy that includes co-delivery of both INS-RTB and
CTB/LTB/STB-GAD may suppress a greater variety of autoreactive Thl lymphocytes or
provide the ability to block disease progression at later stages of diabetes onset.
The results of this enterotoxin B subunit-mediated autoantigen tolerization study
have shown that oral administration of CTB-autoantigens to NOD mice can significantly
reduce pancreatic islet inflammation (insulitis score) to levels found in previous
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intravenous or intraperitoneal CTB injection experiments. A change in the dominant
effector lymphocyte population from Thl to Th2 following ligand-autoantigen
inoculation was predicted based on detection of a significant increase in IgGl antibody
isotype production. The CTB-GAD5 fusion protein was found to mediate an overall
reduction in insulitis when compared to tolerization with CTB or GAD5 peptide alone.
This result indicated that genetic linkage of the CTB adjuvant protein to GAD5
autoantigen could dramatically enhance GAD5 presentation to autoantigen specific Tcells. Heat denaturation of CTB-GAD5 fusion proteins altered the fusion protein
structure in a way that eliminated assembly of CTB-GAD5 monomers into pentameric
structures and reduced, but did not eliminate, CTB-GAD5 suppression of insulitis in
comparison with non-denatured CTB-GAD5 fusion protein. The extent of insulitis
suppression that remains after heat denaturation may be due in part to residual
adjuvanticity of the toxin B subunit-autoantigen fusion protein which, being a part of a
pathogenic protein complex, may likely contain pathogen associated molecular patterns
(PAMPs) that bind antigen presenting cell (APC) toll-like receptors and therefore elicit
an enhanced immune response. Inoculation of NOD mice with the CTB-GAD5
containing bacterial cell lysate significantly suppressed insulitis development in
comparison with inoculation with CTB alone and uninoculated animals. Based on the
results of antibody isotype experiments, the contribution of other E. coli proteins and
lipopolysaccharides (LPS) in the bacterial lysate may have helped to stimulate the highest
Th2 response identified in all of our ligand-autoantigen treatments tested. This result
may be due in large part to the presence of LPS in the bacterial cell extract known from
previous studies to enhance Th2 immune responses (Tian, J. et al., 2001). Enhancement
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of the Th2 lymphocyte response through B subunit ligand-autoantigen fusion protein
interactions with bacterial proteins or LPS demonstrates the feasibility of using bacterial
cells expressing CTB-GAD5 and other AB toxin B subunit-autoantigen fusion proteins as
effective oral subunit vaccines for suppression of autoimmune diabetes and for use in the
treatment of other Thl lymphocyte mediated autoimmune diseases such as multiple
sclerosis or rheumatoid arthritis.
The multiple bands seen in Figure 5 A represent stages of self-assembly of
CTB/LTB/STB-GAD5 monomers into their pentameric forms (lanes 2-4). The fusion
proteins identified in Figure 5, panels A and B were identified by specific antibody
staining with anti-Flis and anti-GAD antibodies. The apparent anomalies in the
molecular weights of several of the protein bands may be due to post-translational
alterations in the native glycosylation pattern as a result of expression in E. coli.
Alternatively, unexpected small shifts in banding patterns may be due to differences in
the electrophoretic mobility of the proteins being separated under non-denaturing
conditions.
The principal enterocyte membrane receptor for CTB and LTB is Gmi
ganglioside, although LTB is known to interact to a lesser extent with asialo-GMi,
lactosyl ceramide, and several additional glycoproteins. The glycolipid
globotriaosylceramide (Gbs) is the principal receptor of STB. Both LTB-GAD5 and
STB-GAD5 fusion proteins generated levels of insulitis reduction comparable to CTBGAD5. The retention of LTB-GAD5 and STB-GAD5 pentamer binding affinity for their
natural membrane receptors was demonstrated by Gmi and Gba ELISA assays (Figure 6).
Both ligand-fusion proteins stimulated a significant increase in IgGl antibody titers,
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suggesting an increase in the Th2 lymphocyte response that indicates the
immunomodulatory effects generated by LTB and STB may be similar to those generated
by CTB under conditions where the toxin B subunit ligands are fused to autoantigens
(Rappuoli, R. et al., 1999; Williams, N.A. et al., 1999). The diversity of receptor binding
among the B subunit-autoantigen fusion proteins suggests that oral co-inoculation with
CTB, STB, LTB, and RTB ligand-autoantigen fusion proteins could generate additive or
possibly synergistic increases in peripheral tolerance that could completely suppress
diabetes symptoms and provide therapy for those already afflicted with the disease.
One potential disadvantage of pentameric toxin B subunit-autoantigen fusion
proteins is the size limitation imposed by the linked autoantigen for pentamer assembly to
occur. When the linked autoantigen was greater than 20 kDa, a dramatic decrease in
pentamer formation was observed (Arakawa, T. et al, 1998b; Arakawa, T. et al, 1999).
When GAD55 was fused with CTB, only the monomeric form of CTB-GAD55 was
detected using immunoblot methods. Thus, assembly of fusion protein pentamers may be
limiting for maintenance of autoantigen carrier capacity and may impact additional
adjuvant functions provided by the toxin B subunit. The ricin toxin B subunit provides a
unique monomeric carrier option for the delivery of larger autoantigens to the mucosal
immune system than can be delivered by the pentameric toxin B subunits. Our criterion
for choosing an N-tenninal fusion of INS to RTB was based on examination of the RTB
protein structure, which revealed that the N-terminus is located further away from cell
receptor binding sites than the C-tenninus and extends outward from the molecule. We
found that the INS-RTB fusion protein generated a significant reduction in insulitis in
comparison with INS inoculated NOD mice. Thus, it is clear that N-terminal autoantigen
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fusions to RTB retain biological activity, as confirmed by asialofetuin binding assays
(Figure 6). Furthermore, recent experiments have shown that the carboxyl-terminus of
RTB can also be used to attach foreign antigens without a perceived interference of
receptor binding (Medina-Bolivar, F. et al, 2003). Thus, the possibility for linkage of
foreign or self antigens to either the RTB N- or C-termini may permit construction of
RTB adjuvant based multivalent vaccines for more effective protection against
autoimmune and infectious diseases. Increases in anti-insulin IgGl antibody titers
detected following oral inoculation with the INS-RTB fusion protein suggests that a Th2
lymphocyte-mediated bystander suppression mechanism of immune tolerance may be the
dominant immunological pathway by which RTB-autoantigen fusion proteins suppress
autoimmune diabetes insulitis symptoms. This possibility awaits further confirmation by
secreted cytokine analysis experiments. Oral administration of CTB-INS and CTB-GAD
fusion proteins indicate that the amount of autoantigen required for suppression of
autoimmune diabetes can be significantly reduced from earlier estimates. Due to the
potent immunostimulatory nature of CTB when linked to foreign proteins (GeorgeChandy, A. et al, 2001), autoantigen fusions with CTB may also stimulate serum and
mucosal anti-CTB IgG and IgA humoral antibody responses, which may bind to CTB and
thereby reduce its effectiveness as a mucosal carrier for immunotolerization. This effect
may require an increased number of oral ligand-autoantigen fusion protein
administrations to generate satisfactory levels of immune suppression. To circumvent
this potential obstacle, our research has demonstrated that LTB, STB, and RTB can all be
used as efficient alternative adjuvant molecules for oral autoantigen delivery through the
gut.
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Our experimental data suggest the feasibility of using a variety of AB enterotoxin
B subunit proteins to stimulate suppression of insulitis in prediabetic mice. We have
demonstrated for the first time the use of STB and RTB as potential adjuvants for
improved oral tolerance of an autoimmune disorder. Treatment with a combination of
ligand-autoantigens may provide additive or synergistic levels of insulitis suppression
which may correlate with prevention of hyperglycemia and serve as an effective strategy
for prevention and therapy for Type 1 diabetes and other Thl mediated autoimmune
diseases in humans.
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Figure 4: Diagram of E. coli pRSET(A) Expression Vectors.
cDNA fragments encoding the cholera toxin B subunit (CTB), the heat-labile enterotoxin
B subunit (LTB), the shiga toxin B subunit (STB), and the ricin toxin B subunit (RTB)
were fused to the pancreatic islet autoantigens glutamic acid decarboxylase (GAD) and
proinsulin (INS). A 5 kDa C-terminal epitope of human GAD (GAD5) was fused to the
C-termini of CTB, LTB, and STB. In addition, a 55 kDa secreted form of human GAD
(GAD55) was fused to the C-terminus of CTB. Proinsulin (INS) was linked to the Nterminus of RTB. The fusion protein cDNAs were inserted into the multiple cloning site
of the E. coli expression vector pRSET(A). This vector includes the bacteriophage T7
promoter for generating high expression levels of inserted genes and a hexahistidine
sequence for Ni2+-column affinity purification of ligand-autoantigen fusion proteins.
Additional components of the pRSET(A) vector can add up to 9 kDa increase in size to
each construct expressed.
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Figure 5: Immunoblot Identification of Renatured Enterotoxin B Subunit-Autoantigen
Fusion Protein Synthesized in E. coli.
Panel A: Protein bands identified by anti-GAD primary antibodies: Lane 1 = GAD5.
Lane 2 = CTB-GAD5. Lane 3 = LTB-GAD5. Lane 4 = STB-GAD5. Lane 5 = CTBGAD55. Panel B: Proteins identified with anti-His primary antibody: Lane 1 = GAD5
molecule. Lane 2 = CTB. Lane 3 = CTB-GAD55. Lane 4 = CTB-GAD5. Lane 5 = LTBGAD5. Lane 6 = STB-GAD5. Lane 7 = INS-RTB. Arrows indicate pentameric
molecules.
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Figure 6: Detection of Pentameric and Monomeric Enterotoxin B Subunit Receptor
Binding by ELISA.
Refolded toxin B subunit-autoantigen fusion proteins were added at increasing
concentrations to the wells of 96-well microtiter plates. Insulin-RTB {solid line) wells
were coated with asialofetuin receptor molecules; STB-GAD5 {dash-dotted lines) wells
were coated with globotriaosylceramide (Gb3) receptor molecules; CTB-GAD5 and LTBGAD5 wells {dashed lines) were coated with Gmi ganglioside receptor molecules. Light
emission from triplicate samples were measured as relative light units (RLU) and
displayed on the y-axis. Enterotoxin B subunit-autoantigen fusion protein concentrations
are shown on the x-axis. Relative light unit values were normalized to background
chemiluminescence levels in wells containing the autoantigen alone or phosphate
buffered saline (PBS). Variation among triplicate samples was too small to represent
graphically with error bars.
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Figure 7: Histopathological Examination of Non-Obese Diabetic (NOD) Mice Pancreatic
Islet Tissues.
Representative islets of Langerhans from inoculated mice were scored according to
advancing pancreatic islet inflammation (insulitis) by the following criteria, as indicated
in the following images: Score = 0 (normal islets), no autoreactive lymphocytes detected
in or near the islet. Score = 1 (peri-insulitis), extravasation of effector lymphocytes from
an adjacent blood vessel and partial surrounding of the islet by autoreactive lymphocytes.
Score = 2 (invasive insulitis), 20 - 40% islet invasion by cytotoxic lymphocytes,
dendritic cells and macrophages. Score = 3 (intra-insulitis), 40 - 70% lymphocyte
infiltration of islet. Score - 4 (severe insulitis), entire islet infiltrated by cytotoxic
lymphocytes and APC’s.
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Figure 8: Degree of Severity of Insulitis in Prediabetic Mice Orally Inoculated with E.
co/z'-Generated Toxin B Subunit-Autoantigen Fusion Proteins.
Five-week old female NOD mice were gavaged with 50 ng of autoantigen alone or with
toxin B subunit-autoantigen fusion proteins. Mice were sacrificed at 10 weeks of age and
pancreas tissue excised, fixed, stained, embedded in paraffin and sectioned for light
microscopic examination of pancreatic insulitis as described in the section on Methods.
Panels A, C, E show the insulitis scores expressed as the mean for each experimental
animal inoculation group. Error bars represent the 95% confidence interval. Panels B, D.
F show the gradation of insulitis scores expressed as percent of the total number of islets
(n > 15) measured for each experimental group. Panels A/B compare the effects of
autoantigen size and carrier/adjuvant ligand pentamerization on the level of insulitis
suppression generated by CTB-GAD5, CTB-GAD55, pentamerized CTB-GAD5 (- heat)
and monomeric CTB-GAD5 (+ heat).
Panels C/D compare three pentameric
carrier/adjuvants for their relative effects on mediating GAD suppression of insulitis in
mice tolerized with CTB-GAD5) LTB-GAD5 and STB-GAD5. Panels E/F show a
statistical reduction in insulitis when insulin is fused to RTB than when given alone.
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Figure 9: Serum Antibody Isotype Titers Detected in Ligand-Autoantigen Inoculated
NOD Mice.
Sera from 5 to 8 mice within the same experimental group were pooled to determine
average antibody levels for all animals in the group, thus no error bars are indicated.
Serum anti-GAD and anti-insulin IgGl and IgG2c antibody titers were measured by
chemiluminescent ELISA as described in the section on Methods. Increased levels of
IgGl in the tolerized animal groups suggest a dominant Th2 cell response (immune
suppression) while increases in IgG2c levels suggest Thl cell activation (inflammatory
response). In panel A. sera from NOD mice orally inoculated with CTB-, LTB-, and
STB-GAD fusion proteins were incubated with rabbit anti-GAD primary antibodies,
followed by reaction with mouse anti-rabbit IgGl or IgG2c secondary antibodies
conjugated with alkaline phosphatase. In panel B, sera from proinsulin or INS-RTB
inoculated NOD mice were incubated with rabbit anti-insulin primary antibodies,
followed by incubation with mouse anti-rabbit IgGl or IgG2c secondary antibodies
conjugated to alkaline phosphatase as described in the section on Methods.
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Table 3: Experimental NOD Mouse Inoculated Groups
Protein Delivered
Animal Group
(50 ^g/gavage)
(n = 8)
1.
2.
3.
4.
5.

(-) control (PBS only)
CTB
CTB-GADs
CTB-GAD5 (heat denatured)
CTB-GADs (E. coli extract)

6.

CTB-GAD55
LTB-GADs
STB-GADs
GAD5
INS
INS-RTB

7.

8.
9.
10.
11.
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Table 4: Average Insulitis Score in
Adjuvant-Autoantigen Inoculated Mice
Insulitis Score
(Mean ± S.E.)

Group
(-) Control (PBS only)
CTB
INS
CTB-GADs (+ heat)
GAD5
ltb-gad5
STB-GADs
CTB-GADs (cell lysis)
CTB-GAD55
CTB-GADs (- heat)
INS-RTB

80

3.5 ± 0.24
2.5 ± 0.29
1.9 ±0.25
1.6 ±0.19
1.5 ±0.25
1.4 ±0.22
1.2 ±0.20
1.2 ±0.21
1.0 ±0.16
1.0 ±0.18
0.9 ±0.19

Table 5: Percent of Healthy Islets in AdjuvantAutoantigen Inoculated Mice______________
% Healthy Islets t

Group*
(-) Control (PBS only)
CTB
INS
GAD5
CTB-GADs (+ heat)
ltb-gad5
INS-RTB
CTB-GAD55
CTB-GAD5 (cell lysis)
STB-GAD5
CTB-GAD5 (- heat)

19.2
36.6
41.6
51.7
54.5
60.2
65.2
66.6
67.1
70.5
71.4

* Based on histological examination of 15 or
more islets per animal.
t
Healthy islets = insulitis score of 0.
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Abstract
Onset of Type 1 diabetes (T1D) occurs when autoreactive lymphocytes destroy
the insulin-producing beta-cells in the pancreatic Islets of Langerhans. The progressive
lack of insulin and subsequent onset of hyperglycemia results in increased damage to
nerves, blood vessels, and tissues manifested by development of a host of severe disease
symptoms leading to premature death. To enhance restoration of immunological
homeostasis by lymphocytes mediating the suppression of autoimmunity, the B chain of
the plant AB enterotoxin ricin, a castor bean lectin binding a variety of epidermal cell
receptors, was genetically linked to the coding region of the proinsulin gene and
expressed as a fusion protein in transformed potato plants. This work is the first
documented example of a plant enterotoxin B subunit linked to an autoantigen and
expressed in transgenic plants for enhanced immunological suppression of Type 1
diabetes autoimmunity.

INDEX ENTRIES/KEYWORDS: Ricin B chain, insulin, type 1 diabetes, autoimmune,
oral tolerance, transgenic plant, potato.
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Introduction
The delivery of autoantigens by mucosal routes has long been pursued as a means
of prevention, suppression, and/or treatment of autoimmune disorders through
stimulation of immune tolerance (reviewed in Faria, A.M. and Weiner, H.L., 2006). For
Type 1 daibetes, the autoantigen of choice for generation of oral tolerance is frequently
insulin (Zhang, ZJ. et al., 1991; Hancock, W.W. et al., 1995; Polanski, M. et al, 1997;
Maron, R. et al, 1999; Wang, H. et al, 2000; Maron, R. et al, 2001). Immune tolerance
generated towards an autoantigen by oral delivery of the antigen was shown to reduce
disease symptoms in several animal models of autoimmune disease. However, a
substantial amount of insulin is required for oral tolerance in humans. Insulin inoculated
at 10 - 50 mg/wk for 12 wk followed by an equivalent monthly maintenance dose was
required for 50% suppression of Type I diabetes symptoms of insulitis and
hyperglycemia (Ziegler, A.G. et al, 1989). However, it was shown that autoantigen
dosage can be reduced substantially when the autoantigen is linked to a bacterial A-B
enterotoxin adjuvant (Bergerot, I. et al, 1997; Arakawa, T. et al, 1998b; Ploix, C. et al.
1999; Aspord, C. and Thivolet, C., 2002; Sadeghi, H. et al, 2002; Petersen, J.S. et al,
2003; Denes, B. et al, 2005; Yuki, Y. et al, 2005; Li, D. et al, 2006; Gong, Z. et al,
2007; Ruhlman, T. et al, 2007) or co-delivered with an adjuvant (Bregenholt, S. et al,
2003). In most cases, the adjuvant used to stimulate an immune response has been the
cholera toxin B protein chain (CTB). The CTB oligomer is pentameric protein consisting
of five identical subunits that bind for the most part to GMi ganglioside—a glycolipid
found in apical membranes of all epithelial cells and especially the intestinal epithelium
(Frey, A. et al, 1996). Genetic linkage of the CTB gene at either its N or C terminus
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with genes encoding a diabetes autoantigen such as insulin or glutamic acid
decarboxylase (GAD), can be expressed and retained in the cytoplasm of transgenic plant
cells for large-scale production of the immunomodulated autoantigen. The purified
fusion protein is assembled in the plant into pentamers consisting of five CTBautoantigen subunits arranged in a doughnut configuration that, when delivered to
animals susceptible to or displaying new onset autoimmune diabetes, were shown to
suppress the development of autoantigen-specific inflammatory T-lymphocytes. A recent
strategy for prevention of autoimmune destruction of the pancreatic beta cells was shown
to involve exposure of mucosal epidermal cell receptors to self-reactive proteins
(autoantigens) such as insulin, which results in the recruitment of T helper cells (Th2)
and regulatory T-cells (TregS) that retard the destructive process (Sgouroudis, E. and
Piccirillo, C.A., 2009). Because large amounts of insulin would be required to treat the
estimated 65,000 diagnosed cases of new onset T1D worldwide per year (International
Diabetes Federation, www.idf.org), edible plants were assessed as a potentially
inexpensive production and delivery system for the synthesis of human insulin (Arakawa,
T. et al, 1998b). The biological mechanisms that underlie bacterial exotoxin B subunit
protein stimulation of inflammatory or immune suppression responses remain
incompletely understood. However, low doses of antigen favor active suppression of
inflammation, while higher doses cause deletion or inactivation (anergy) of antigenspecific lymphocytes (Fowler, E. and Weiner, H.L., 1997). Major players identified
among the lymphocyte classes activated for immune suppression include T-helper 2
(Th2) cells, Th3 cells, Trl cells, CD4+CD25+ regulatory cells, FoxP3+and latencyassociated peptide (LAP+) regulatory T-cells. For a review of the role that these
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lymphocytes play in down regulation of inflammatory responses in oral tolerance, see
Faria, A.M. and Weiner, H.L. (Faria, A.M. and Weiner, H.L., 2005).
Our laboratory efforts have been focused on development of immunomodulated
autoantigens synthesized in edible plants for enhanced prevention of infectious disease or
for immunological suppression of autoimmunity (Arakawa, T. et al, 1998b; Yu, J. and
Langridge, W.H., 2001; Kim, T.G. and Langridge, W.H., 2003; Kim, T.G. et al, 2004a;
Kim, T.G. et al, 2004b; Kim, T.G. et al, 2004c; Kim, T.G. et al, 2004d; Lee, J.Y. et al.
2004; Choi, N.W. et al, 2006b, 2006c, 2006a; Shin, E.A. et al, 2006). The initial goal of
the work presented here was to determine whether the plant synthesized ricin enterotoxin
B subunit linked to an autoantigen such as insulin could be synthesized in transformed
plants. Establishment of transformed edible plant tissues expressing significant amounts
of RTB-insulin can establish the basis for assessment of RTB-insulin maintenance of
immunological homeostasis and euglycemia in new onset Type 1 diabetes. Early
experiments showed that the cholera toxin B chain, when conjugated to insulin, lowered
the effective autoantigen dose by approximately 5,000-fold for prevention of diabetes
onset in the non-obese diabetic (NOD) mouse T1D model (Ploix, C. et al, 1999). While
the non-toxic B subunit lectin portion of bacterial A-B toxins was shown to be an
effective adjuvant in previous experiments, several obstacles were encountered that could
limit the usefulness of these A-B toxins when linked to antigens or autoantigens. For
example, all the aforementioned toxin B subunit protein chains from bacteria require
subunit pentamerization for maximum binding to cell-surface Gmi carbohydrate
receptors. Further, large fusion proteins may generate steric hindrance thereby limiting
pentamer formation, resulting in a reduction in the transfer of antigenic proteins across

86

intestinal cell membrane surfaces to underlying immune cells in the lamina propria. An
additional concern is that many individuals have had prior exposure to diarrhea-inducing
exotoxins and may possess memory T- and B-cells that can rapidly generate a
neutralizing antibody response to these proteins if re-encountered as part of a vaccine
therapy. Therefore, based on its properties as a plant protein, we selected the untested
ricin toxin B chain (RTB) from the castor bean plant (ricinus communis) to assess its
potential application as an immunomodulatory molecule capable of enhancing
immunosuppression to a linked T1D autoantigen. It is known that RTB is a galactosecontaining (lectin) molecule capable of binding to epidermal cell glycolipids and
glycoproteins with terminal galactose residues. Since the ricin B chain is monomeric, it
is capable of binding to a wider variety of membrane receptors than the bacterial toxin B
chains. The ricin toxin B chain is taken up into epidermal cells by multiple mechanisms
including endocytosis and since it is of plant origin, it is more likely to fold properly to
form biologically active immunomodulatory molecules in transgenic plants. In addition,
previous exposure of ricin to humans resulting in the generation of neutralizing
antibodies is essentially non-existent due to the high level of lethality of the intact A-B
toxin and the present absence of a commercial vaccine for the civilian population. Since
consideration of RTB for application as an immunomodulator and carrier molecule,
several reports have demonstrated the expression of properly folded RTB in transgenic
plants (Medina-Bolivar, F. et al., 2003; Reed, D.G. et al, 2005). Further, the efficacy of
RTB enhancement of vaccines against infectious disease has also been demonstrated
(Choi, N.W. et al, 2006b, 2006c, 2006a).
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Recent experiments in our laboratory have compared the protective effects of
different diabetes-specific autoantigens such as human proinsulin (INS) and glutamic
acid decarboxylase (GAD), following conjugation to lectin adjuvants (Carter III, J.E. et
al., 2006). These adjuvants included the B chains of cholera toxin—CTB, the heat-labile
enterotoxin—LTB from enterotoxigenic Escherichia coli, the enterotoxin B chain from
shigella—STB, and the plant toxin ricin B subunit—RTB. Each enterotoxin B subunit
fusion protein was expressed in transgenic E. coli and purified extracts were delivered to
non-obese diabetic (NOD) mice by oral gavage as a widely accepted T1D animal model.
All fusion proteins tested generated a significant increase in the enhancement of
autoantigen-mediated immune suppression of pancreatic inflammation (insulitis). The
insulin-RTB fusion protein monomer was shown to contain an unusually high number of
cysteine residues (15 total). This large number of cysteine residues was found to reduce
correct RTB protein folding to less than 8% of the purified fusion protein refolded in a
buffer optimized for protein refolding (unpublished data). Interestingly, the
predominantly denatured form of RTB retained immunostimulatory activity in
comparison with mice fed unconjugated INS or buffer only. However, the maximum
level of RTB as an immunomodulatory molecule could not be adequately assessed since
the denatured RTB molecule lacked receptor-binding ability. Therefore, to obtain a
population of properly folded ricin-autoantigen fusion proteins, the INS-RTB fusion
protein DNA construct was introduced into eukaryotic cells through the construction of
transgenic potato plants capable of producing the natively-folded insulin-RTB fusion
protein (see Methods Section). In addition to the INS and RTB genes, a beta-phaseolin
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(P) signal sequence from Phaseolus vulgaris was inserted at the insulin N-terminus to
facilitate synthesis and storage of P-INS-RTB in the endoplasmic reticulum.
Plant expression systems offer unique advantages for the production of
pharmaceutical compounds. Plant transformation can be time consuming and technically
demanding. However, once transformed plants have been generated they are capable of
producing kilograms of therapeutic protein for a fraction of the cost of biopharmaceutical
products isolated from transgenic microorganisms (Gavilondo, J.V. and Larrick, J.W.,
2000). Since plants are eukaryotes, they are capable of synthesizing proteins with the
correct post-translational modifications providing the correct pattern of protein folding
required for human immunotherapy. The construction of plant-produced
immunomodulated vaccines for protection against autoimmunity, antibodies, and other
medically or agriculturally important drugs have been reviewed extensively (Carter III,
J.E. and Langridge, W.H.R., 2002; Boehm, R., 2007; Floss, D.M. et al., 2007).

Materials and Methods
Construction of Plant Expression Vector pPCV701 P-INS-RTB
Oligonucleotides containing suitable restriction endonuclease sites were
introduced 5’ and 3’ to the genes encoding beta-phaseolin (P), human proinsulin (INS),
and ricin toxin B chain (RTB) by routine polymerase chain reaction (PCR) methods.
Following PCR amplification, the isolated gene-containing DNA fragments were ligated
to create the fusion product Xbal-P-SacI-INS-Hindlll-RTB-Smal. The resulting fusion
sequence was inserted into the multiple cloning site of pPCV701_MCS, a modified plant
expression vector previously described (Koncz, C. et al, 1987) as seen in Figure 10. The
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modified plant expression vector contains a microsomal retention signal encoding
sequence—SEKDEL (Munro, S. and Pelham, H.R., 1987; Wandelt, C.I. et al, 1992;
Haq, T.A. et al, 1995) located downstream from the multiple cloning site. The SEKDEL
sequence causes the P-INS-RTB fusion protein to be sequestered in the endoplasmic
reticulum via golgicistemae recycling, which allows the fusion protein to build up in
concentration. The source of the INS gene was from plasmid pPCV701_CTB-INS, a
construct designed in our lab for expression in plants that contains human proinsulin
linked to the cholera toxin B chain (Arakawa, T. et al, 1998b). The phaseolin-RTB
plasmid template DNA was obtained from Dr. Lynne M. Roberts, University of
Warwick, U.K. and is described in Frigerio, L. et al (1998). All restriction enzymes,
ligase, polymerase, and accompanying buffers were purchased from New England
Biolabs, Ipswich, MA. All PCR conditions used in the cloning experiments were
identical: 32 cycles, 94°C initial DNA melting for 5 min (30 sec for subsequent cycles),
55°C for 30 sec of primer annealing, and 72°C for 1 min of DNA replication of the
complementary strand and polymerization. The completed pPCV701 P-INS-RTB
plasmid (Figure 10) was transferred into Agrobacterium tumefaciens strain GV3101
pMP90RK for transformation of potato plants after verification of the correct DNA
sequence. The correct DNA sequences were confirmed by PCR amplification of P-INSRTB gene fusion and restriction enzyme digestion of the plasmid DNA with Xbal/Smal
to produce the anticipated 1.14 kb P-INS-RTB fragment. In addition, DNA nucleotide
sequencing was performed on regions that span upstream and downstream to the P and
RTB genes, respectively, to check for correct gene insertion into the plasmid.
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In Vivo Plant Transformation
Potato plants (Solanum tuberosum cv. Bintje) were grown in Magenta GA-7
culture boxes (Sigma, St. Louis, MO) on Murashige and Skoog (MS) basal medium
(Murashige, T. and Skoog, F., 1962) containing 3.0% sucrose and 0.22% Gelrite at 20°C
in a light room under cool white fluorescent tubes (12 pE) set on a 16 hr photoperiod
regime. A. tumefaciens colonies that contain the pPCV701_P-INS-RTB plasmid were
selected on yeast extract broth (YEB) solid media with antibiotics, prepared as follows:
5.0 g/L beef extract, 1.0 g/L Bacto™ yeast extract, 5.0 g/L Bacto™ peptone, 5.0 g/L
sucrose, 0.1 g/L MgSCLYFLO, pH = 7.2; 18 g/L agarose, autoclaved then cooled to 55°C
before adding 100 mg/L carbenicillin, 25 mg/L gentamycin, 50 mg/L kanamycin, and 50
mg/L rifampicin. Plant stem sections (~1 cm) were excised from ~1 month old plants
with a sterile scalpel and immersed in 10 ml of liquid MSO media (Table 6) containing
~0.6 O.D. culture of transformed ^4. tumefaciens and 250 pi of 14.8 mMacetosyringone to
induce Agrobacterium infection. After incubation with the bacteria, the stem cuttings
were placed onto PI solid medium (Table 6) for two days in the light room to continue
Agrobacterium-mQ&iatQd T-DNA integration into the plant genomic DNA. The
Agrobacterium-mocxx\atQ& stem explants were briefly Washed free of excess bacteria by
brief vortexing in MSO media containing 100 mg/L erythromycin before incubating the
explants on Pl-S plates (Table 6) in the light room. The stem explants were transferred
to fresh Pl-S plates every 7-10 days to prevent bacterial growth. After one month of
growth on callus fonnation medium, the stem explants were transferred to P2-S plates
(Table 6) until shoot development. New shoots (-1 cm) were cut with a sterile scalpel
and placed upright into P3-S medium (Table 6) for root induction. Putative transformed
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plants were vegetatively propagated in Magenta boxes (Sigma, St. Louis, MO) under
sterile conditions until sufficient plant material could be obtained for analysis of
transgene expression.

Plant DNA Extraction
Genomic DNA was extracted from >2 cm-wide sterile transgenic plant leaves
using the Qiagen DNeasy plant mini kit (Qiagen #69104, Valencia, CA) with the
following adaptations to the kit protocol: 1.) Leaves from the putatively transformed
plants were homogenized in liq. N2 with a mortar and pestle. 2.) After suspension of the
powdered leaf material with lysis buffer included in the Qiagen kit, two rounds of
centrifugation at 20,000 x g for 5 min were performed to eliminate excess plant debris.
3.) Approximately 40 - 50 mg of leaf material was used per QIA shredder mini spin
column (half-capacity) to reduce impurities and improve DNA isolation. 4.) The spin
columns were washed three times with 100% ethanol to thoroughly remove plant
compounds that inhibit PCR. 5.) The plant genomic DNA was eluted twice from the
columns using 50 pi each of 65°C DNase-free sterile water (100 pi final volume).
The plant DNA concentration was measured by UV spectrophotometry at 260 nm.
The DNA concentration from each plant sample was normalized to 20 ng/pl and then
separated by electrophoresis on a 0.8% agarose gel that was subsequently stained with
ethidium bromide (EtBr). The EtBr-stained DNA bands were visualized by UV light
fluorescence to verify the integrity of the extracted genomic DNA.
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Identification of INS-RTB Gene in Transformed Plants by
Polymerase Chain Reaction
Two sets of optimized primers were constructed to amplify segments of DNA
spanning the INS-RTB gene fusion and the kanamycin-resistance neomycin
phosphotranspherase selectable marker gene (NPT), respectively. The NPT forward
primer (5’-GAACAAGATGGATTGCACGCAGGT-3’) was complementary to
nucleotides at position 7 - 30 of the Tn5 NPT gene. The NPT reverse primer
(5’-ATGTTTCGCTTGGTGGTCGAATGG-3’) was complementary to position 394 417. The INS forward primer (5,-ACGAGGCTTCTTCTACACACCC-3’) was
complementary to position 63 - 86 of the human proinsulin gene. The RTB reverse
primer (S’-ACTGTTCCCTGATGTCGCTGC-S’) was complementary to position 319342 of the ricin toxin B chain gene. Independent PCR reactions for each set of primers
was performed using 10 pmol/primer (2 pi each), 100 ng plant DNA template (5 pi each),
2.5 mMdeoxynucleotidetriphosphates (5 pi), and 1 pi of REDTaq polymerase (Sigma
#D-8187, St. Louis, MO) in 5 pi of the supplied lOx buffer and brought up to 50 pi with
DNAse-, RNAse-, and protease-free water. Each 50 pi reaction mixture was initially
melted at 95 °C for 5 min, followed by 40 cycles of melting for 30 sec. at 95°C, 90 sec.
annealing at 59°C, 45 sec. of polymerization at 72°C. PCR products were analyzed by
2% agarose gel electrophoresis and bands visualized by UV illumination of EtBr-stained
DNA.
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Verification of Amplified Sequences from Transformed Plants by
Restriction Endonuclease Digestion
PCR products generated from transformed plant DNA using INS-RTB primers
were cleaned up with the QIAquick® nucleotide removal kit (Qiagen #28304, Valencia,
CA). The eluted genomic DNA concentration was normalized to 40 ng DNA/pl per
sample. The samples were subjected to //zW//7 digestion for 2 hours at 37°C to cleave
the 5,-AAAGCTT-3’site located between INS and RTB gene segments. Undigested vs.
digested PCR products were visualized by UV light fluorescence in an EtBr-stained 2%
agarose gel following elecrophoretic separation of the DNA bands.

Tissue Print Immunoblot
Tubers grown from genetically transformed plants were initially screened for
protein expression by “stamping” potato slices onto a nitrocellulose membrane, followed
by standard immunoblot protein identification techniques. Transformed potato plants
were maintained in sterile Magenta boxes on P3 solid media until tuber formation (~3 - 4
months). Three separate tubers from each of three transformed plants (Q, S, and U) were
cut ~1 cm from the tuber ends, then placed cut-side down onto 100 x 25 mm culture
plates containing solid P4 protein induction media (Table 6). After one week of
incubation on P4 media, the tuber slices were gently dabbed onto Kimwipe tissue to
remove excess moisture and media. Next, the incubated tuber surfaces were firmly and
evenly pressed onto a sheet of dry nitrocellulose paper (NitroBind 0.45 micron transfer
membrane, MSI, Westboro, MA #EP4HY00010) to transfer proteins from the tuber slice
to the membrane. To increase adsorption of soluble proteins onto the nitrocellulose
membrane, the sheets were prepared for protein adsorption by soaking them for 15 min in
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200 mM CaCl2 and allowed to air dry prior to tissue printing. Transformed and control
tuber slices were stamped onto the membrane in triplicate using three different tubers per
plant specimen. The stamped membrane was blocked for 1 hr at room temperature (R/T)
by incubating with 5% non-fat dry milk in Tris-buffered saline (TBS)—20 mMTris, 500
mMNaCl, pH = 7.5. Following a five min wash in TEST (TBS + 0.05% Tween-20), the
membrane was incubated overnight at 4°C with 1:500 monoclonal mouse anti-human
insulin antibody (Advanced ImmunoChemical Inc, Long Beach, CA #HG 1-211, clone
7F8) diluted with 1% non-fat milk in TEST. The membrane was then washed 3x, 5 min
each with TEST and incubated for 2 hr at R/T with 1:2,000 goat polyclonal anti-mouse
IgG conjugated to alkaline phosphatase (Sigma #A-7686). Finally, the membrane was
washed 3x, 5 min each with TEST, lx with TBS, then soaked in Lumiphos Plus
chemiluminescent substrate (Lumigen, Southfield, MI) for 5 min. Luminescence from
the tissue blotted membrane was detected in a Hamamatsu low light imaging system
using MetaMorph™ software to quantify the luminescence signal emitted from each
tissue slice print sample.

Immunoblot Detection of P-INS-RTB in Purified Extracts of
Plant Tissues
Tubers were sliced ~1 mm thick under sterile conditions and incubated on P4
induction media (Table 6) for 72 hours to induce protein expression by stimulation of the
mas promoter. After auxin stimulation of protein synthesis, slices were stored frozen at 80°C. Frozen tissue was homogenized in liquid N2 using a mortar and pestle. Excess
ground tissue was stored at -80°C for further analysis by Asialofetuin ELISA (see
below). Ground tissue was mixed 1:1 (w/v) with chilled denaturing extraction buffer—

95

DEB (8 M urea, 100 mMNaCl, 100 mMTris, and 0.1% Tween-20, pH = 8.0). The
mixture was vortexed briefly, then centrifuged at 14,000 RPM for 15 min at 4°C to pellet
plant debris. The supernatants containing soluble plant proteins were mixed 1:2 with
denaturing Laemmli buffer containing 5% |3-mercaptoethanol and boiled for 10 min. The
samples were then separated by 10% sodium dodecylsulfate polyacrylamide gel
electrophoresis (SDS-PAGE). Gel electrophoresis was run for 1.5 hours at 100 V in Trisglycine buffer (25 mMTris-Cl, 250 mMglycine, 0.1% SDS, pH = 8.3). Immunoblot
transfer of the plant proteins onto nitrocellulose membrane with a semi-dry
electrotransfer apparatus (Sigma) was performed at 70 mA for 2 hr using standard
techniques (Sambrook, J. et al., 1989). The membrane was blocked with 40 ml of 5%
nonfat milk in TEST overnight at 4°C. Mouse anti-RTB monoclonal antibodies (clones
RB127, RB691, and RB732—Santa Cruz Biotechnology #sc-52191, #sc-52194, and #sc52195, respectively) were diluted 1:500 each (400 ng/ml final) in 15 ml TEST plus 1%
nonfat milk and applied to the membrane overnight at 4°C. Unbound antibodies were
washed from the membrane with ~30 ml of TEST 5x (5 min each wash). Goat anti
mouse polyclonal antibodies conjugated to horseradish peroxidase—HRP (Pierce
#1858413) were diluted 1:5,000 (2 ng/ml final) in 15 ml TEST plus 1% nonfat milk and
incubated with the membrane for 1 hr at R/T with gentle shaking. The membrane was
washed 5x with TEST (5 min each) and lx with TBS (10 min). A total of 4 ml Super
Signal West Femto chemiluminescent substrate (Pierce #34094) containing 2 ml of
LuminoEenhancer plus 2 ml stable peroxide solution was applied by surface tension onto
the membrane and incubated for 5 min in the dark. Chemiluminescence was detected on
Classic Blue Autoradiography Film EX (MIDSCI #BX57, St. Louis, MO).
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Quantitation of RTB Lectin Activity in P-INS-RTB Plants by
Asialofetuin-ELISA
Wells of an irradiated polystyrene (high binding) opaque white, flat-bottom
Costar®microplate (Coming Inc. #3922, Lowell, MA) were incubated O/N at 4°C with
100 ql/well of 10 [ig/ml asialofetuin (Sigma #A-4781) prepared in bicarbonate buffer, pH
= 9.6. Unbound well surfaces were then blocked with 300 ql/well of 5% nonfat milk
O/N at 4°C. Previously prepared frozen tuber homogenates (see materials and methods
immunoblot section) were mixed 1:1 (w/v) with chilled plant extraction buffer—PEB
(200 mMTris base, 1% citric acid, 1% PVP-10, 0.1% Tween-20, pH = 7.7) containing
2% protease inhibitor cocktail (Sigma P-8340) and centrifuged at 14,000 RPM, 15 min at
4°C. Supernatants containing cmde soluble protein extracts were applied in triplicate
(100 ql/well) to the asialofetuin-coated 96-well microtiter plate and incubated for 1 hr at
R/T with mild shaking at ~45 RPM on a G2 Gyrotory® shaker (New Bmnswick Scientific
Co., Inc., Edison, NJ). The wells were washed 4x, 5 min each with 300 pl/well
phosphate-buffered saline + 0.05% Tween-20 (PBST) to remove non-specific plant
proteins. A mixture of mouse anti-RTB monoclonal antibodies from clones RB127,
RB257, RB363, RB691, RB732, RB944, and RB999 (Santa Cruz Biotech #sc-52191~7,
respectively) was diluted 1:200 (1.0 ng/ml final) in 1% nonfat milk/PBST and added to
the microplate at 100 pl/well. After 1-hour incubation with the primary antibodies, the
wells were washed 4x with PBST (5 min each). A 1:5,000 dilution (2 ng/ml final
concentration), of goat polyclonal anti-mouse IgG-HRP (Pierce #1858413) prepared in
1% nonfat milk/PBST was added at 100 pl/well and incubated for 1 hr at R/T with
shaking. Wells were washed 4x, 5 min each with PBST followed by a final rinse with
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PBS (300 |jl/well). SuperSignal Pico West (Pierce #34079) chemiluminescent substrate
was prepared following the manufacturers instructions and added to wells at 100 pl/well
for 1 min with shaking in the dark. Light emmission at 425 nm was measured within 5
min of applying substrate in a microtiter plate luminometer (Berthold Technologies
Micro LumatPlus LB 96V). Relative light units were determined by subtracting
background signal from PBS control wells. Untransformed Bintje negative control plant
extracts were compared to P-INS-RTB-expressing plants by evaluating mean relative
light units (RLU) +/- 95% confidence intervals (C.I.).

Results
Detection of the P-INS-RTB Gene Fusion in Transformed Potato Plants
Approximately 30-40 ng/pl of genomic DNA was isolated from 40-50 mg of
frozen transformed potato leaf homogenate. Mature leaves (> 2 cm wide) were selected
for DNA extraction because they were found to have less PCR inhibitors than immature
leaves (unpublished data). Nine putative transformed plants were analyzed by PCR,
labeled as plants A, J, K, L, P, Q, R, S, and U. Three plants (Q, S, and U) consistently
yielded amplified products of the correct anticipated molecular weight when using both
NPT primers (Figure 11 A) and INS-RTB primers (Figure 1 IB). When digested with
//mJ///restriction endonuclease (Figure 3-2C), the INS-RTB PCR product for each of
the three transformed plants were cleaved into the 197 and 347 bp DNA fragments
expected for RTB and insulin, based on cleavage of the single Hindlll site located
between INS and RTB gene fusion products (refer to Figure 10 and Figure 11C).
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Detection of P-INS-RTB Fusion Protein Synthesis in
Transformed Potato Tissues by Tissue Immunoprinting
The tissue immunoprint revealed highest binding of anti-insulin antibody to PINS-RTB protein residue from plant U, with somewhat less binding to plant S as
compared to the untransformed Bintje prints (Figure 12). RTB expression levels
appeared to be greatest in cell layers immediately underlying the epidermal layer of cells.
Although levels of bioluminescence characteristic of P-INS-RTB expression were
detectable, plant Q was not considered to be statistically significant in P-INS-RTB
expression in comparison with untransformed Bintje tuber prints (Figure 12B).

Immunoblot Detection of P-INS-RTB in Plant Crude Extracts
Crude extracts from putatively transformed plants Q, S, and U all showed antiRTB specific bands (Figure 13), although the protein appeared predominantly as large
aggregates. Extracts from plants J, L, and P as well as the untransformed Bintje negative
control did not react with anti-RTB antibodies. This result was as expected based on the
lack of a detectable gene fusion product in the PCR results. A plant extract from potatoes
expressing phaseolin linked to ricin B chain (P-RTB) previously produced in our lab by
Dr. Nak-Won Choi was used as a positive control (+), as was commercial RTB (+’)
purified from castor bean plants (Sigma L-9639). The expected 31.5 kDa band for PRTB and 29 kDa band for RTB was detected, although aggregate multimers were also
observed.
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Detection of RTB Lectin Activity in P-INS-RTB Plants by
Asialofetuin-ELISA
Crude soluble extracts from plants Q, S and U were analyzed for the presence of
P-INS-RTB with properly folded RTB, as indicated by the ability to bind asialofetuin—a
galactose-terminating glycoprotein that serves as a ligand for natively folded RTB
(Fulton, R.J. et al., 1986). All three plants demonstrated a significantly higher signal
from crude extracts than did the untransformed potato extract (P<0.05), although plants Q
and U were only marginally significant (Figure 14).

Discussion
Agrobacterium-medmtGd transformation of potato plant stems with T-DNA that
contains the P-INS-RTB gene fusion resulted in the regeneration of nine putatively
transfonned plants. Evaluation of plant genomic DNA for the presence of integrated PINS-RTB genes by PCR using two different primer sets showed that three of the plants
consistently yielded amplicons of the correct size. Based on the PCR results, the three
transgenic plants (Q, S, and U) were analyzed for the presence of the P-INS-RTB fusion
protein by tissue immunoprinting with anti-human insulin monoclonal antibodies. The
tissue immunoprinting procedure provided a rapid method to evaluate the location and
intensity of relative transgenic protein expression in tuber slices without resorting to the
extraction of soluble protein in experimental buffers that can often lead to protein
denaturation or proteolysis of target proteins. Direct application of transformed tuber
hand cut sections to the membrane permited specific antibody capture of even improperly
folded or insoluble recombinant proteins. Thus, the tissue printing method permitted the
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maximum opportunity for immunological confirmation of the presence of transgenic
insulin-RTB protein depending upon the availability and accessibility of suitable primary
and secondary antibodies. In Figure 12, the tuber tissue immunoprint data demonstrated
significant amounts of the P-INS-RTB recombinant protein in tuber tissue slices from
plants S and U, even permitting morphological identification of sub-epidermal cell layers
as generating the highest P-INS-RTB gene expression levels in the live tissues slices.
Based on quantification of chemiluminescence from the tuber immunoprints, transformed
plants S and U were shown to generate the highest P-INS-RTB fusion protein levels in
stem cell layers located immediately basal to the tuber epidermis, a cambial layer in
which cell proliferation is highest. This result suggests that recombinant P-INS-RTB and
other recombinant proteins may be expressed at their highest levels in rapidly dividing, as
yet undifferentiated plant tissues.
Extracts from the transformed and untransformed plants were evaluated by
Western blotting to confirm the immunospecificity and expected molecular weight of the
P-INS-RTB fusion protein. Initial attempts to detect immunospecific protein bands at
significant quantities were hampered by the presence of what appeared to be endogenous
protease activity, by weak stimulation of the mas promoter, and/or by other physical
losses that occurred during insulin-RTB protein isolation and purification protocols. The
expression level of P-INS-RTB in potato plant extracts was often difficult to detect by
Western blot using individual monoclonal antibodies. Often, antibodies from several
clones were combined to yield detectable signals. The use of anti-RTB polyclonal
antibodies was also somewhat problematic based on a large degree of non-specificity that
occurred during the performance of Western blotting and ELISA techniques. This result
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may have occurred due to the fact that the commercial antibodies were generated by
injecting the A-B enterotoxin isolated from castor bean plants rather than the recombinant
A-B toxin into animals, which may have inadvertently produced cross-reactive antibodies
against common proteins or sugar moieties on glycosylated protein structures common to
both castor bean and potato plants. New batches of antibodies were tested with similar
results suggesting that the common banding pattern was not due to antibody degradation.
Although distinct bands of P-INS-RTB protein were eventually identified by
Western blot using anti-RTB monoclonal antibodies (Figure 13), the proteins appeared as
large (>250 kDa) aggregates. Further attempts to disassociate the aggregate into the
expected 40.8 kDa band for P-INS-RTB protein were inconclusive, even following
incubating the samples in sample cracking buffer at different temperatures and with
various concentrations of SDS, chaotropes (i.e. 8 M urea), and several reducing agents,
including beta-mercaptoethanol, dithiothreitol, and Tris[2-carboxyethyl] phosphine
TCEP (unpublished data). We suspect that the unusually large number of cysteine
residues (six residues in insulin and nine residues in RTB) may have resulted in aberrant
disulfide bond formation with partially denatured cysteine-rich proteins in plant crude
extracts leading to significant intermolecular disulfide bond formation leading to the
formation of insulin-RTB molecular aggregates. A minor decrease in protein aggregation
was achieved through reduction of cysteine disulfide bonds with 100 mM TCEP followed
by alkylation of the resultant sulfhydryl groups with 100 mM of iodoacetamide to prevent
reestablishment of disulfide linkages (data not shown). Tuber extracts of P-INS-RTB
protein prepared from plants S and U in PEB retained the ability to bind asialofetuin,
which suggests that a significant amount of RTB may be folded natively by the plants
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and may have only aggregated after partial denaturation, as seen in the immunoblot
(Figure 13).
Based on the numerous steps during sample preparation that may have caused
partial P-INS-RTB protein denaturation, it remains unclear as to the percent of total PINS-RTB fusion protein that was originally natively-folded in the plant. However, from
this study, it is clear that transformed edible plants synthesize significant amounts of
soluble, biologically active P-INS-RTB that can be effective for immunological
suppression of T1D. Results from our previous experiments using bacterial-synthesized
INS-RTB for immune suppression in juvenile NOD mice showed a significant level of
prevention of diabetes new onset, even when >90% of the RTB protein was denatured
(Carter III, J.E. et al, 2006). Thus, bacterial synthesized INS-RTB suppression of Type
1 diabetes indicates that INS-RTB synthesized in plants may be even more effective as a
vaccination strategy for autoimmune diabetes prevention as it is well known that plant
production systems may provide appropriate eukaryotic post-translational modifications
that preserve and enhance the biological functions of the recombinant protein.
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Figure 10: Map of Plant Expression Vector pPCV701_P-INS-RTB.
Genes located within the T-DNA borders flanked by the right and left 25 bp direct
repeats (RB and LB) include: The A. tumefaciens mas P2 promoter; the beta-phaseolin
signal peptide (P), the human proinsulin gene (INS), the ricin toxin B chain (RTB) gene,
followed by the SEKDEL endoplasmic reticulum sequestration signal; the g7pA
polyadenylation signal is from gene 7 in the A. tumefaciens Tl-DNA; a beta-lactamase
gene (Bla) for detection of ampicillin resistance in E. coli and carbenicillin resistance in
A. tumefaciens. On the Pi side of the mas dual promoter is the OcspA polyadenylation
signal from the A. tumefaciens octopine synthase gene; the pNOS promoter is from the A.
tumefaciens nopaline synthase gene; a NPTII (neomycin phosphotransferase II)
expression cassette for kanamycin resistance, permitting selection of transfonned plants;
the g4pA polyadenylation signal is from A. tumefaciens gene 4 in the Tl-DNA (Koncz,
C. et al., 1987).

106

107

Figure 11: PCR Identification of P-INS-RTB DNA in Transgenic Potato Plants.
Panel A: PCR products of plant DNA extracts using primers specific for the kanamycin
resistance gene (neomycin phosphotransferase—NPT). The 411 bp NPT amplicon can
be seen in all plant DNA PCR products except for plants K and R, which appear to have
truncated fragments. Panel B: PCR detection of the INS-RTB gene fusion with primers
that span both genes. Only plants Q, S, and U had PCR products of the expected 544 bp
size, which were further assessed by digestion with Hindlll restriction endonuclease.
Panel C: Hindlll digestion of PCR products from plants Q, S, and U showing the
expected DNA fragments (347 bp and 197 bp) when cleaved at the Hindlll restriction site
between INS and RTB. (-): Untransformed Bintje genomic DNA PCR product; (+):
PCR product from pPCV701_P-INS-RTB plasmid DNA template extracted from E. coli
host (strain HB101); mw: Molecular weight markers.
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Figure 12: Tissue Immunoprint Detection of INS-RTB Fusion Protein in Transgenic
Tubers.
Panel A: Potato tuber slices incubated one week on P4 protein induction media were
stamped onto a dry nitrocellulose membrane, blocked with non-fat milk, and then stained
with mouse anti-human insulin monoclonal antibody (IgG). After washing in TEST, the
membrane was incubated with goat anti-mouse IgG polyclonal antibodies conjugated to
alkaline phosphatase, then visualized by chemiluminescence with the substrate LumiPhos™. The presence of P-INS-RTB fusion protein was detected using a Hamamatsu
low light imaging system. Circled areas indicate regions analyzed for light intensity with
the MetaMorph software. Panel B: The mean light intensity was calculated for three
transfonned plants (Q, S, and U) in triplicate and compared with untransformed Bintje
potato (-).

110

kDa

25015010075-

5037-

2520-

111

Figure 13: Immunoblot Detection of P-INS-RTB Fusion Protein in Tuber Extracts.
Anti-RTB specific bands appeared in lanes containing crude extracts from plants Q, S,
and U, although the protein is heavily aggregated. The untransformed Bintje (-) control
plant extract showed no reactivity to the anti-RTB antibodies. Crude extracts from plants
J, L, and P also did not react with the monoclonal antibodies, which confirms the PCR
data that the plants are either not transformed or perhaps partially-transformed chimeras
with low P-INS-RTB yields. Positive controls containing P-RTB (minus the INS gene)
from potatoes previously generated in our lab—labeled (+), and commercial RTB (50 ng)
purified from castor beans—labeled (+’), both reacted with anti-RTB antibodies. The
expected size of 31.5 kDa for P-INS (+) and 29 kDa for RTB (+’) were seen, as were
additional bands that appear to be multiples of aggregated RTB due to insufficient
reduction of the unusually high number of disulfide bonds present.
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Asialofetuin ELISA of Plant Extracts
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Figure 14: Asialofetuin-Binding ELISA of Crude Potato Plant Extracts.
Wells of a 96-well microtiter plate were coated with asialofetuin—a glycoprotein that
binds to natively-folded RTB. Crude extracts from potato tubers incubated on P4 protein
induction media were applied to the wells and analyzed by chemiluminescent detection of
anti-RTB labeled proteins. Plant S demonstrated the highest level of expression of PINS-RTB with RTB lectin activity.
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Table 6: Formulas for Plant Growth Media
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MSO = Murashige and Skoog salt and vitamin mixture (Gibco #10632-057)
S
= Antibiotic selection (excluded from untransformed control Bintje plants)
BA = Benzyl adenine
IAA = Indole acetic acid
GA3 = Gibberellic acid
Km = Kanamycin-—kills untransformed plant cells
Cf
= Cefotaxime/Claforan—bactericidal
Er = Erythromycin—^bactericidal, less toxic to plants
NAA = alpha-Naphthaleneacetic acid—a plant auxin, used to stimulate the mas promoter
2,4-D = 2,4-Dichlorophenoxyacetic acid—a synthetic auxin; more stable than NAA
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CHAPTER FOUR
CONCLUSIONS
In Chapter 2, several bacterial and plant toxin B chain adjuvants were compared
for their ability to enhance immunotolerization of an autoantigen. Although each type of
adjuvant has its own warrants and limitations, they may prove to be more effective for
immune suppression of autoimmune disease when applied in conjunction with each other.
The enterotoxin B chain adjuvants usually bind distinct cell-surface receptors. Based on
the results of these experiments, a form of immunotherapy could be devised in which
multiple adjuvants, each one fused with identical antigens, could be co-delivered by the
mucosal route to maximize uptake and immune suppression. Alternatively, multiple
adjuvants conjugated with individual antigenic epitopes could be engineered to establish
a multivalent vaccine that functions against a variety of pathogen serotypes (i.e. human
immunodeficiency virus or influenza virus mutants) or alternatively, a multicomponent
vaccine against several pathogen species, provided in a single vaccine dose. Another
option would be to prime the immune system with particular antigen(s) linked to a single
adjuvant, followed by delivery of a subsequent immunization booster dose with the same
antigen(s) linked to a different adjuvant. This would favor generation of antibodies
against the antigen(s) of interest, rather than boosting the production of antibodies
directed against the carrier molecule. A similar approach could be pursued for the oral
tolerization of autoimmune disorders. Alternatively, an assortment of autoantigenadjuvant conjugates could be generated to induce immunotolerance to a large spectrum of
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known self-reactive proteins for a particular autoimmune disease such as, rheumatoid
arthritis or multiple sclerosis.
Chapter 3 reveals a promising approach to the production of an autoimmune
disease protective vaccine generated in edible transgenic plants. However, there may be
issues that require resolution before plant-based vaccination becomes widely accepted.
Of considerable concern is the safety of patients who might possibly overdose on
antigen-laden plant tissues, potentially inducing tolerance to infectious disease. Of
additional concern is the possibility for initiation of autoimmune disease symptoms in
disease-free individuals who accidentally consume autoantigens linked to a strong
bacterial adjuvant. Several studies have reported that oral administration of autoantigens
may actually exacerbate autoimmune disease (Genain, C.P. et al., 1996; Bellmann, K. et
al, 1998; Blanas, E. and Heath, W.R., 1999). Throughout the past decade however, no
instances of autoimmune disease have been reported following application of
recombinant proteins. Experiments remain to be performed that will determine the
optimum dose and frequency of immuno-modulated autoantigen delivery required to
achieve the maximum protective efficacy from plant-based vaccines. Vaccine dosage
and frequency requirements may vary with each type of autoimmune disease.
Plants generally produce relatively small amounts of recombinant protein, which
correlates with potential limitations in the amount of antigen that can be introduced by
direct consumption. Recent techniques have been devised to improve foreign protein
yield of various therapeutic proteins in plants. These methods include chloroplast
transformation, alteration of transgene codon usage to better match tRNA’s normally
synthesized in plants, and the inclusion of chaperone genes (Sutton, D.W. et al, 1992; De
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Cosa, B. et al, 2001). Protein chaperones promote the correct folding of nascent
polypeptides following protein synthesis and help to protect the protein from
ubiquitination and proteolytic degradation. Chloroplast transformation, in combination
with chaperonin protection, has allowed foreign protein concentrations in tobacco to
reach levels as high as 46.1% of total soluble protein (TSP), (De Cosa, B. et al, 2001).
Although these protein yields are high in proportion to the percent of soluble protein in
the plant, the actual protein quantity may still be relatively low in certain specific plant
tissues where only small amounts of total protein is made (e.g. leaves). Eventually, the
maximum amount of foreign protein a plant can produce and still remain viable may be
reached. In addition,, transformed plants may occasionally show signs of stunted
growth at higher levels of transgene expression.
The use of adjuvants and carrier-peptides that target epithelial M cells adjacent to
the Peyer’s patches in the lamina propria of the intestine have enhanced the efficiency of
antigen uptake. This may resolve the dilemma of low antigen or autoantigen expression
levels in plants. However, secretory antibodies generated against carrier molecules such
as CTB may potentially block vaccine protein attachment to M cells, reducing uptake of
the linked fusion protein antigens.
Ethical issues regarding recombinant DNA mediated immunotherapy are more
likely to subside as the public becomes more adequately informed concerning the safety
of genetically modified organisms (GMO). Over the past decade since 1999, over 2
trillion transgenic plants were grown with no negative reports of compromised biosafety
in humans (Stewart, C.N., Jr. et al, 2000). Remaining concerns lie in the choice of the
protein synthesized in plants. For example, the Bacillus thuringiensis (B.t.) gene encodes
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an endotoxin insecticide that kills butterfly, Lepidoptera and beetle, Coleoptera pest
species as well as some nematode crop pests. In preliminary studies, pollen from B.t.producing com was shown to negatively impact Monarch butterfly caterpillars, as
evidenced by decreased appetite, growth rate, and increased mortality incidence when the
larvae were fed milkweed leaves dusted with Bt-containing pollen (Losey, J.E. et al.
1999). In contrast, chemical pesticides cause much more harm to the ecosystem,
indiscriminately killing beneficial and harmful insects alike. In favor of using
recombinant insecticides, in 1997 the application of B.t. to cotton crops reduced toxic
chemical pesticide applications by over 900,000 kg (Gianessi, L.P. and Carpenter, J.E.,
1999). Another B.t. gene encoding the Cry9C toxin from B. thuringiensis subspecies
Tolworthi was engineered into com. However, this constmct was deemed potentially
unsafe for humans by the Environmental Protection Agency, because the insect toxin
because it was shown that protein regions of the toxin were shown to be similar to other
proteins known to be allergenic to humans. Inadvertently, the com found its way into the
consumer market and allegedly resulted in food allergic reactions in 28 individuals.
However, the Centers for Disease Control (CDC) tested semm from these individuals
with an ELISA binding assay and none were found to have BT-Cry9C IgE antibodies
(National Center for Environmental Health, 2001). The CDC report concluded that
although there was no detectable evidence of hypersensitivity caused by Cry9C com,
they could not completely mle out this possibility, due to the potential for undetectable
levels of IgE or allergies in the absence of an IgE antibody response. Another concern
regarding transgenic plants is the potential for development of allergic responses
resulting from differences in post-translational modification of proteins by plants. Since
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plants glycosylate proteins somewhat differently than other organisms, plant-made
proteins may induce an allergic response in certain individuals that were not allergic to
the native source of the protein. However, to our knowledge, no reports of adverse
reactions to plant-made foreign proteins have occurred due to differences in
glycosylation. The risks involved with consuming recombinant vaccine plants appears to
be no more threatening than eating a particular food product for the first time, not
knowing a priori what the allergic outcome may be.
Prior to release of vaccine-containing plants into the environment, certain
precautions or guidelines must be observed to ensure their safety. For example,
molecular mechanisms can be installed that will eliminate the ability for cross-pollination
with wild-type species. Chloroplast transformation is one possibility, since it does not
involve altering the nuclear genes present in pollen. Transformed plants must be easily
identified as being medicinal, possibly by the addition of genes encoding the expression
of different colored plant pigments. This would be particularly useful for those with
allergic concerns. Extensive screening tests can be conducted to determine the possibility
for development of allergy from foreign proteins expressed in plants. Especially
important will be dissemination to the consumer of information about the safety of a
genetically altered food product. Pending the outcome regarding safety and efficacy of
directly consuming vaccine plants, administration may be limited to encapsulated freezedried forms or processed and sold in labeled packages. With each successful clinical
trial, confidence in the expediency of using edible vaccines for disease prevention in the
population will increase in the both scientific, corporate and private sectors.
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The molecular and biochemical studies presented within this doctoral dissertation,
demonstrate for the first time the ability for INS-RTB fusion protein arrest of type 1
diabetes autoimmunity. The experiments described here show that INS-RTB suppression
of autoimmune responses provides a basis for development of pluripotent adult or
totipotent embryonic stem cell repopulation of the pancreas with insulin producing beta
cells for restoration of euglycemia and return of the type 1 diabetic patient to a durable
state of immunological homeostasis. The further establishment of complete immune
suppression of diabetes will help to ensure both preventive and interventional therapy for
type 1 diabetes in patients suffering from this life-long chronic inflammatory
autoimmune disease. The application of INS-RTB in combinatorial vaccination
protocols now opens the way not only for prevention and intervention in type 1 diabetes
but for effective immune suppression of many additional organ-specific autoimmune
diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, uveitis,
Graves disease and Hashimoto’s thyroiditis.
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APPENDIX A
FACTORS AFFECTING PROTEIN SOLUBILITY AND
REFOLDING TO THE NATIVE STATE
•

Chaotropic solubilizers: Examples—High molar urea or guanidine HCL. Use 6 - 8 M urea rather
than 6 M guanidine HCL for proteins destined for use in animal/human experiments (guanidine is
toxic).

•

Protein concentration: Use 10 - 100 pg/ml to reduce intermolecular aggregation and improve
solubility.

•

pH: Use a pH that is at least 1-2 orders of magnitude away from the protein isoelectric point (pi) but
not below pH of 3 or above pH of 10 to avoid lysis of the peptide bond and amino acid racemization.
Alkaline (pH > 8) will facilitate an oxidizing environment for disulfide bond formation.

•

Oxidation/Reduction potential: Incorrect disulfide bond formation will cause misfolding of proteins.
Start with sufficient levels of reducing agent (DTT, reduced glutathione, etc.) to break all disulfide
bonds until 2° structure can form and then gradually return to an oxidizing environment to establish
correct disulfide bonds. Can also use oxidized and reduced glutathione in a 1:5 to 1:10 ratio to
facilitate disulfide bond reshuffling (ex. 0.1 mM ox. glut. + 1.0 mM red. glut).

•

Detergents: Prevents intermolecular aggregation of hydrophobic surfaces. Use <2% Tween 20 or 0.1
- 1.0% Triton X-100. Use in 1st dialysis step only if protein will be used for animal/human studies.
Note that Triton X-100 does not dialyze out well.

•

Buffer: Maintains pH during dialysis. Use organic (10 - 100 mM Tris) or inorganic (10 - 100 mM
PBS). Some inorganic buffers will precipitate proteins because of the salts used.

•

Hydrophobic additives: Block undesirable hydrophobic interactions with 1 - 50% ethylene glycol
(start with 5%) or glycerol (5 - 10%).

•

Salt: Can tie up water molecules for “salting in”, but can also precipitate proteins by “salting out”.
Higher concentrations (150 - 500 mM) prevent non-specific binding of proteins with the purification
matrix (e.g. Ni2+-column) but may result in precipitation of eluted protein.

•

Co-solutes/osmolytes: May suppress aggregation of proteins. L-arginine-HCL (0.5 M) has + charged
guanidine group and is the most alkaline amino acid, but can denature some proteins. 0.1% glycine
has also been used to help with refolding.

•

Chelators: EDTA (10 mM) is used to remove imidazole and Ni2+ following the elution step in metal
affinity chromatography. However, if metal cofactors are needed for folding or active sites, EDTA
will bind up metal ions. Use in 1st dialysis step only.

•

Temperature: Refolding is mildly temperature dependent between 4°C and 37°C, but usually
dialysis/refolding is carried out at 4°C to slow the rate of misfolding and reduce contaminating microbe
and protease activity.
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APPENDIX B
BEST PROTEIN SOLUBILITY AGENTS
Adapted from: Bondos, S.E. and Bicknell, A. 2003. Analytical Biochemistry. 316:223-231.
•

Kosmotropes: MgS04 (0 - 0.4 M), (NILLSCU (0 - 0.3 M). Too high will salt proteins out of
solution.

•

Weak kosmotropes: NaCl, KC1 (0-1 M).

•

Chaotropes: CaCl2 (0 - 0.2 M), MgCl2 (0 - 0.2 M), urea (0 - 1.5 M). Too high will denature
proteins.

•

Amino acids: Glycine (0.5 - 2%), L-arginine (0-5 M). May interact with proteins at certain pH and
salt cone.

•

Sugars: Sucrose (0 - 1 M), glucose (0 - 2 M), lactose (0.1 - 0.5 M).

•

Polyhydric alcohols: Glycerol (5 - 40% v/v).

•

Detergents: Tween 20 (0 - 120 pM), Tween 80 (0 - 0.2% w/v), Nonidet P-40 (0 - 1%).

Other Additives
•

Dithiothreitol (DTT)—In low concentrations will inhibit the formation of non-native disulfide bonds.

•

Trifluoroethanol or trichloroacetic acid—Prevent aggregation by stabilizing a-helical structure.

•

Ethanol—Weakens hydrophobic interactions that facilitate aggregation.

•

Detergents—Native structure of membrane proteins may require detergents or micelles.

•

Salts—Nucleic acid binding proteins often require higher salt concentrations.
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APPENDIX C
PROCEDURE FOR RAPID SCREENING OF
OPTIMAL PROTEIN REFOLDING BUFFERS
1.

Incubate Coming Costar™ High-binding polystyrene 96-well microtiter plates with either a ligand to
the target protein or antibodies that recognize the target protein. Add 100 pi per well and incubate O/N
at 4°C.
2. Dump out excess liquid and block wells with 1% BSA or 5% non-fat milk in Tris-buffered saline +
0.05% Tween-20 (TEST).
3. Wash wells lx with 300 pIAvell TBS, 5 min.
4. Prepare tissue/cell homogenate in various chilled buffer combinations (create a table of formulas and
well designations).
5. Spin mixtures at 14,000 RPM, 15 min., 4°C and save the supernatant.
6. Add 100 pFwell of supernatant and incubate for 30 min. at R/T with gentle shaking.
7. Wash 3x with TEST, 5 min each (300 pIAvell).
8. Detection of folded/biologically active protein:
• For ligand-coated wells, add 100 pIAvell 1° Ab raised against the target protein. Only properly
folded target protein will bind to the ligand-coated wells. Denatured proteins will have been
washed off.
• For antibody-coated wells, add 100 pFwell of a substrate/recipient compound that interacts with
the target protein bound to the antibody-coated wells. If the target protein is an enzyme, the
catalytic product can be detected. Otherwise, a 2° Ab specific to the substrate can be used for
detection.
9. Wash 3x with TEST, 5 min each (300 pIAvell).
10. Add 100 pFwell of enzyme/dye-conjugated antibodies for 1 hr at R/T (e.g. anti-IgG conjugated to
horse-radish peroxidase or alkaline phosphatase).
11. Wash 4x TEST, lx TBS, (5 min each).
12. Add colorimetric or chemiluminescent substrate and measure signal. Compare signal strength relative
to negative and positive controls. The highest signal will indicate the best buffer formula for protein
renaturation.
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APPENDIX D
OPTIMIZATION OF PLANT EXTRACTION BUFFER TO YIELD
NATIVELY FOLDED RTB WITH LECTIN ACTIVITY
Buffer 1: 200 mM Tris base, 150 mM NaCl, 400 mM sucrose, 10 mM EDTA, 1% citric acid, 0.1%
Tween-20, 2% protease inhibitor cocktail—Sigma P-8340, pH = 7.4.
Buffer 2: 1:2 frozen leaf tissue plus ice-cold 0.1 M potassium phosphate buffer (pH = 7.0), 5 mM DTT,
protease inhibitor cocktail. (Source: Medina-Bolivar, F. e/a/., 2003. Vaccine. 21:997-1005).
Buffer A: 200 mM Tris base, pH = 8.5
Buffer B: 200 mM Tris base, pH = 8.5 + 200 mM MgS04
Buffer C: 200 mM Tris base, pH = 8.5 + 200 mM KC1
Buffer D: 200 mM Tris base, pH = 8.5 + 100 mM CaC12
Buffer E: 200 mM Tris base, pH = 8.5 + 100 mM MgC12
Buffer F: 200 mM Tris base, pH = 8.5 + 20% glycerol
Buffer G: 200 mM Tris base, pH = 8.5 + 0.1% Triton X-100
Buffer H: 200 mM Tris base, pH - 8.5 + 0.1% Tween 20
Buffer I: 200 mM Tris base, pH = 8.5 + 0.5% Nonidet P-40 substitute
Buffer J: 200 mM Tris base, pH = 8.5 + 0.5% glycine
Buffer K: 200 mM Tris base, pH = 8.5 + 1.0 M L-arginine
Buffer L: 200 mM Tris base, pH = 8.5 + 0.1% polyethylene glycol (PEG) 3350
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APPENDIX E
LINEAGE MAP OF LEUKOCYTE SUBSETS
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